造血干细胞移植(hematopoietic cell transplant, HCT)受者，尤其是接受异基因移植者，发生各种感染的风险较高，**具体取决于移植后免疫缺陷程度、病原体暴露情况和移植后时间长短。HCT患者有感染细菌、真菌、病毒和/或寄生虫的风险，且这些感染性疾病的并发症发病率和死亡率均高于免疫功能正常者**。

本专题使用“造血干细胞移植”泛指任何来源的造血干细胞(例如，骨髓、外周血、脐血)移植。这些造血干细胞可能来自患者自身细胞(自体)；同卵双胞胎[同基因，HLA全相合]；同胞、亲缘或者非亲缘供者(异基因；HLA全相合、半相合或不相合)或脐血(脐血；HLA全相合、半相合或不相合)。(参见 [“造血干细胞的来源”](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

本文将讨论HCT后感染，并按照风险期和临床综合征来分类阐述；此处讨论的综合征常为感染性但也可能存在非感染性病因。HCT受者的感染评估和预防详见其他专题。(参见 [“造血干细胞移植前的感染评估”](https://www.uptodate.cn/contents/zh-Hans/evaluation-for-infection-before-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“造血干细胞移植受者感染的预防”](https://www.uptodate.cn/contents/zh-Hans/prevention-of-infections-in-hematopoietic-cell-transplant-recipients?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“成人造血干细胞移植受者侵袭性真菌感染的预防治疗”](https://www.uptodate.cn/contents/zh-Hans/prophylaxis-of-invasive-fungal-infections-in-adult-hematopoietic-cell-transplant-recipients?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“造血干细胞移植受者的病毒感染预防”](https://www.uptodate.cn/contents/zh-Hans/prevention-of-viral-infections-in-hematopoietic-cell-transplant-recipients?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“造血干细胞移植候选者和移植受者的免疫接种”](https://www.uptodate.cn/contents/zh-Hans/immunizations-in-hematopoietic-cell-transplant-candidates-and-recipients?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

**感染风险若要预测哪些患者最可能受益于靶向预防、诊断性操作和/或抢先治疗，需识别出感染高危人群并确定最高风险的程度和时期。感染风险取决于至少3个因素的相互作用** ([图 1](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=ID%2F50448&topicKey=ID%2F1403&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&rank=1%7E150&source=see_link))：

●致病微生物的相对毒力及暴露程度

●患者的特异性免疫效应细胞/分子和患者的免疫抑制净状态(类型、程度、速度和持续时间)

●有无组织和/或器官损伤(例如，黏膜炎、肾衰竭、肺损伤)和/或有无使用中心静脉导管

根据这些相互作用，可将患者分为感染高危组或低危组([表 1](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=ID%2F70011&topicKey=ID%2F1403&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&rank=1%7E150&source=see_link))。感染风险随血液系统(具体而言是固有和适应性细胞免疫效应细胞/分子)重建而降低。自体HCT受者通常比异基因HCT受者更快完成免疫重建。多种因素可延迟异基因HCT受者的免疫重建，见下文。HCT后的免疫重建详见其他专题。(参见 [“异基因造血干细胞移植后免疫重建策略”，关于‘免疫重建概述’一节](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation?sectionName=%E5%85%8D%E7%96%AB%E9%87%8D%E5%BB%BA%E6%A6%82%E8%BF%B0&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H6875504&source=see_link#H6875504))

异基因HCT受者中，最重要的感染危险因素包括[[1](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/1)]：

●患者因素：

•年龄较大

•高HCT共存疾病指数(参见 [“确定适合异基因造血干细胞移植的患者”，关于‘风险评估评分系统’一节](https://www.uptodate.cn/contents/zh-Hans/determining-eligibility-for-allogeneic-hematopoietic-cell-transplantation?sectionName=%E9%A3%8E%E9%99%A9%E8%AF%84%E4%BC%B0%E8%AF%84%E5%88%86%E7%B3%BB%E7%BB%9F&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H24292831&source=see_link#H24292831))

•疾病和前期治疗相关因素：

-基础疾病，尤其之前接受了大量治疗(例如，多发性骨髓瘤患者之前长期使用糖皮质激素治疗[[2](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/2)]；慢性淋巴细胞白血病患者之前使用嘌呤类似物治疗[[3](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/3)])(参见 [“慢性淋巴细胞白血病患者的感染风险”](https://www.uptodate.cn/contents/zh-Hans/risk-of-infections-in-patients-with-chronic-lymphocytic-leukemia?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

-既往HCT

-供者和/或受者存在既往感染(参见 [“造血干细胞移植前的感染评估”](https://www.uptodate.cn/contents/zh-Hans/evaluation-for-infection-before-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

-移植前存在巨细胞病毒(cytomegalovirus, CMV)、单纯疱疹病毒(herpes simplex virus, HSV)、水痘-带状疱疹病毒(varicella-zoster virus, VZV)和/或EB病毒特异性免疫

-铁过载

●移植相关因素([表 2](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=ID%2F98314&topicKey=ID%2F1403&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&rank=1%7E150&source=see_link))**：**

•清髓性预处理方案(参见 [“造血干细胞移植的预处理方案”，关于‘清髓性预处理方案’一节](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation?sectionName=%E6%B8%85%E9%AB%93%E6%80%A7%E9%A2%84%E5%A4%84%E7%90%86%E6%96%B9%E6%A1%88&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H5&source=see_link#H5))

•供者/受者HLA不相合的程度，使用不相合或者部分相合(半相合)移植物者感染风险较高(参见 [“造血干细胞移植的供者选择”](https://www.uptodate.cn/contents/zh-Hans/donor-selection-for-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

•移植物来源–与骨髓或脐血干细胞移植相比，外周血干细胞移植时，中性粒细胞植活较快，但慢性移植物抗宿主病(graft-versus-host disease, GVHD)发生率更高；与骨髓或外周血干细胞移植相比，脐血干细胞移植时，中性粒细胞植活、B细胞和T细胞免疫重建较慢，但GVHD发生率较低(参见 [“造血干细胞的来源”](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

•T细胞去除(或CD34+细胞分选，这可有效清除T细胞)与移植排斥风险较高、B细胞和T细胞免疫重建较缓、中性粒细胞减少性感染风险较高、GVHD及其相关感染风险较低以及疱疹病毒和侵袭性真菌感染风险增加和延长有关(参见 [“造血干细胞的来源”，关于‘T细胞处理’一节](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells?sectionName=T%E7%BB%86%E8%83%9E%E5%A4%84%E7%90%86&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H20&source=see_link#H20)和 [“移植物抗宿主病的预防”，关于‘体内TCD’一节](https://www.uptodate.cn/contents/zh-Hans/prevention-of-graft-versus-host-disease?sectionName=%E4%BD%93%E5%86%85TCD&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H263518593&source=see_link#H263518593))

•免疫抑制方案–使用[抗胸腺细胞球蛋白](https://www.uptodate.cn/contents/zh-Hans/133562?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)(antithymocyte globulin, ATG)时，T细胞免疫缺陷更显著；使用[甲氨蝶呤](https://www.uptodate.cn/contents/zh-Hans/92799?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)时，黏膜更易损伤，达到中性粒细胞植活的时间延迟

●免疫遗传学–增加或减少感染风险的基因多态性包括：

•受者甘露糖结合凝集素基因突变多态性与清髓性同胞异基因HCT植活后感染风险增加有关[[4](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/4)]。

•多种基因多态性(在HCT供者、HCT受者或者血液系统恶性肿瘤患者中)与HCT受者和/或血液系统恶性肿瘤患者发生侵袭性曲霉菌病的风险增加有关。包括固有免疫应答相关基因的多态性，如Toll样受体4基因[[5](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/5)]；可溶性模式识别受体基因，即长穿透素3(PTX3)基因[[6](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/6)]；dectin-1基因[[7,8](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/7,8)]；以及其他[[9](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/9)]。

•CMV再激活受抑制与不同的供者活化性杀伤免疫球蛋白样受体基因型有关[[10](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/10)]。

●长期和严重中性粒细胞减少症–癌症支持治疗多国协会(MASCC)风险指数是一个得到验证的中性粒细胞减少性发热相关医学并发症风险测量工具([计算器 1](https://www.uptodate.cn/contents/calculator-multinational-association-for-supportive-care-in-cancer-mascc-risk-index-for-patients-with-neutropenic-fever-not-appropriate-for-children-less-than16-years-of-age?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))[[11-14](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/11-14)]，这个风险指数和其他评估粒细胞减少症相关并发症风险的方法详见其他专题(参见 [“化疗致中性粒细胞减少成人患者的风险评估”](https://www.uptodate.cn/contents/zh-Hans/risk-assessment-of-adults-with-chemotherapy-induced-neutropenia?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

●严重急性和广泛型慢性GVHD及其治疗(尤其是使用大剂量糖皮质激素和新型免疫抑制剂时)，而导致免疫重建延迟(参见 [“移植物抗宿主病的发病机制”](https://www.uptodate.cn/contents/zh-Hans/pathogenesis-of-graft-versus-host-disease-gvhd?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“急性移植物抗宿主病的临床表现、诊断和分级”](https://www.uptodate.cn/contents/zh-Hans/clinical-manifestations-diagnosis-and-grading-of-acute-graft-versus-host-disease?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“慢性移植物抗宿主病的临床表现和诊断”](https://www.uptodate.cn/contents/zh-Hans/clinical-manifestations-and-diagnosis-of-chronic-graft-versus-host-disease?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

●免疫调节病毒感染，尤其是CMV[[15](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/15)]

●移植失败

●呼吸系统并发症，如气流下降[[16](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/16)]

许多感染危险因素相互关联。例如，中性粒细胞减少的持续时间与多种患者和移植因素有关，包括基础疾病、前期大量治疗、干细胞来源(脐血)和细胞剂量(低)、预处理方案(清髓性)以及移植失败或排斥等。与此类似，很多危险因素可增加GVHD风险，包括干细胞来源(外周血干细胞受者风险高于骨髓干细胞受者)和HLA亲缘关系(HLA不相合或供者非亲缘时，风险高于HLA相合亲缘供者时)。

管理HCT受者时，最重要的一点是在移植前仔细筛选供者和受者，以评估移植后感染的风险。(参见 [“造血干细胞移植前的感染评估”](https://www.uptodate.cn/contents/zh-Hans/evaluation-for-infection-before-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“造血干细胞移植的供者选择”](https://www.uptodate.cn/contents/zh-Hans/donor-selection-for-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

感染时间轴HCT受者最易感染的类型可根据移植后时长大致分为3种[[1,17](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/1,17)]。具体如下：

●**植活前–从移植到中性粒细胞恢复，即第20-30日**

●**植活后早期–从植活到移植第100日**

●**植活后晚期–第100日以后**

对于异基因和自体HCT受者，结合各时间段内最可能的感染性疾病表现和可能发生的临床综合征([表 3](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=ID%2F50318&topicKey=ID%2F1403&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&rank=1%7E150&source=see_link))，可提供互补信息。了解各时间段内可能感染的病原体，有助于判断预防治疗的必要性及潜在益处，方便临床医生对发生的临床综合征做鉴别诊断。HCT后发生的许多临床综合征可能存在感染性和非感染性病因。

这种人为的时间轴划分法确实很适合HCT受者的管理。各阶段的时间和时长可能会受一些因素的影响，例如干细胞来源、HLA及次要组织相容性抗原相合程度、预处理的类型及强度、任何去除T细胞或其他细胞群的移植物处理方法、移植后免疫抑制治疗类型(尤其是糖皮质激素)，以及有无GVHD。通常，异基因HCT受者在这3个阶段均存在感染风险([图 2](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=ID%2F52716&topicKey=ID%2F1403&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&rank=1%7E150&source=see_link))，而自体HCT受者仅在植活前和植活后早期易出现感染([图 3](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=ID%2F64491&topicKey=ID%2F1403&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&rank=1%7E150&source=see_link))。在各阶段，患者可能发生细菌、真菌、病毒和/或寄生虫感染，不过某些病原体在某些阶段更易致病([表 3](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=ID%2F50318&topicKey=ID%2F1403&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&rank=1%7E150&source=see_link))。

**HCT受者的感染性并发症一般风险并不仅局限于粒细胞减少阶段，可持续至自体HCT后6-12月或异基因HCT后12-24个月，直至B细胞和T细胞免疫恢复。感染风险增加的时期包括：中性粒细胞极度减少的阶段(中性粒细胞绝对计数≤100/μL)和/或淋巴细胞极度减少的阶段(淋巴细胞绝对计数≤300/μL)** [[1](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/1)]。接受T细胞抑制疗法(高剂量糖皮质激素、抗T细胞抗体、嘌呤类似物等)、发生GVHD和/或接受去T细胞HCT可能延迟T细胞恢复，而[利妥昔单抗](https://www.uptodate.cn/contents/zh-Hans/92827?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)等药物可能延迟B细胞恢复[[18](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/18)]。感染风险常在最后一次使用T细胞抑制疗法后6个月或淋巴细胞绝对计数≥500/μL(或CD4绝对计数≥200/μL)时降低，以其中后达到者为准。(参见 [“异基因造血干细胞移植后免疫重建策略”，关于‘免疫重建概述’一节](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation?sectionName=%E5%85%8D%E7%96%AB%E9%87%8D%E5%BB%BA%E6%A6%82%E8%BF%B0&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H6875504&source=see_link#H6875504))

植活前HCT后植活前，感染的主要危险因素是皮肤黏膜损伤(破坏了天然的皮肤黏膜屏障)和中性粒细胞减少(导致吞噬能力降低)([图 2](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=ID%2F52716&topicKey=ID%2F1403&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&rank=1%7E150&source=see_link)和[图 3](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=ID%2F64491&topicKey=ID%2F1403&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&rank=1%7E150&source=see_link))[[1](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/1)]。

**中性粒细胞减少性发热 — 大部分HCT患者都会在植活前发生中性粒细胞减少性发热。发热性中性粒细胞减少患者中，仅20%-30%有明确的感染源** [[19,20](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/19,20)]。发热往往是感染的唯一证据。中性粒细胞减少性发热患者中，10%-25%经血培养证实有菌血症[[19](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/19)]。该阶段的中性粒细胞减少性发热多由G+和G-需氧菌引起。

除发热外，感染性并发症还可表现为肺炎和下消化道感染[中性粒细胞减少性小肠结肠炎或艰难梭菌(_Clostridioides_ _difficile_)结肠炎]。相对少见的表现包括：脓毒性休克、坏疽性深脓疱和直肠周蜂窝织炎。

抗生素预防可降低中性粒细胞减少期间的细菌感染(主要是菌血症)风险。HCT患者与高危非移植患者的中性粒细胞减少性发热评估和管理方法相似。(参见 [“中性粒细胞减少性发热综合征的概述”](https://www.uptodate.cn/contents/zh-Hans/overview-of-neutropenic-fever-syndromes?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“成人癌症患者中性粒细胞减少性发热的诊断方法”](https://www.uptodate.cn/contents/zh-Hans/diagnostic-approach-to-the-adult-cancer-patient-with-neutropenic-fever?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“血液系统恶性肿瘤成人患者及造血干细胞移植受者(高危患者)的中性粒细胞减少性发热综合征的治疗”](https://www.uptodate.cn/contents/zh-Hans/treatment-of-neutropenic-fever-syndromes-in-adults-with-hematologic-malignancies-and-hematopoietic-cell-transplant-recipients-high-risk-patients?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“造血干细胞移植受者感染的预防”](https://www.uptodate.cn/contents/zh-Hans/prevention-of-infections-in-hematopoietic-cell-transplant-recipients?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“高风险成人化疗诱导中性粒细胞减少期间的感染预防”](https://www.uptodate.cn/contents/zh-Hans/prophylaxis-of-infection-during-chemotherapy-induced-neutropenia-in-high-risk-adults?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

中性粒细胞减少期间，接受清髓性预处理的HCT患者发生感染的风险最高，因为比非清髓性方案有更多黏膜损伤和更长时间中性粒细胞减少。通常推荐这类高危患者接受抗生素预防(参见 [“高风险成人化疗诱导中性粒细胞减少期间的感染预防”，关于‘抗细菌预防性治疗’一节](https://www.uptodate.cn/contents/zh-Hans/prophylaxis-of-infection-during-chemotherapy-induced-neutropenia-in-high-risk-adults?sectionName=%E6%8A%97%E7%BB%86%E8%8F%8C%E9%A2%84%E9%98%B2%E6%80%A7%E6%B2%BB%E7%96%97&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H875811271&source=see_link#H875811271))。

持续性发热的鉴别诊断很多，包括耐药细菌、真菌感染[尤其是假丝酵母菌(_Candida_)，有时还有曲霉菌(_Aspergillus_)]、隐匿性感染、组织损伤的炎症反应和药物热(参见 [“血液系统恶性肿瘤成人患者及造血干细胞移植受者(高危患者)的中性粒细胞减少性发热综合征的治疗”](https://www.uptodate.cn/contents/zh-Hans/treatment-of-neutropenic-fever-syndromes-in-adults-with-hematologic-malignancies-and-hematopoietic-cell-transplant-recipients-high-risk-patients?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))。推荐这类高危患者接受抗真菌预防[[21,22](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/21,22)]。(参见 [“成人造血干细胞移植受者侵袭性真菌感染的预防治疗”](https://www.uptodate.cn/contents/zh-Hans/prophylaxis-of-invasive-fungal-infections-in-adult-hematopoietic-cell-transplant-recipients?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

黏膜炎 — 口腔、口咽及食管黏膜炎在清髓性预处理的患者中最常见，主要原因是方案的黏膜毒性。但HSV血清学阳性且未接受特异性抗病毒预防的患者，有2/3可发生HSV再激活。HSV可加剧黏膜炎[[23,24](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/23,24)]，偶会导致食管炎。抗病毒预防对防止HSV再激活非常有效。罕见情况下，毛霉病致病菌、镰刀菌(_Fusarium_)或其他致病性霉菌引起局部深穿凿样口腔溃疡。(参见 [“造血干细胞移植受者的病毒感染预防”](https://www.uptodate.cn/contents/zh-Hans/prevention-of-viral-infections-in-hematopoietic-cell-transplant-recipients?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“毛霉菌病(接合菌病)”](https://www.uptodate.cn/contents/zh-Hans/mucormycosis-zygomycosis?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

腹泻 — 腹泻是常见的表现，分感染性和非感染性。预处理引起的黏膜损伤是HCT后第1周发生腹泻的常见原因，清髓性预处理后最常见。有些药物也常引起腹泻，尤其是口服镁补充剂(用于治疗钙调磷酸酶抑制剂常导致的低镁血症)。

HCT患者发生感染性腹泻最常见的原因之一是艰难梭菌相关性腹泻(_C. difficile_–associated diarrhea, CDAD)，一些研究显示其发生率可高达10%-30%[[25-28](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/25-28)]。尤其要注意高毒力艰难梭菌所致CDAD的全球患病率日益升高。临床医生应警惕显著腹泻和/或腹痛的患者有无CDAD。(参见 [“成人艰难梭菌感染的流行病学、微生物学和病理生理学”](https://www.uptodate.cn/contents/zh-Hans/clostridioides-difficile-infection-in-adults-epidemiology-microbiology-and-pathophysiology?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

腹泻的另一常见原因是中性粒细胞减少性小肠结肠炎(或者盲肠炎)，常表现为发热、腹泻、腹痛或腹胀，以及压痛，详见其他专题。(参见 [“中性粒细胞减少性小肠结肠炎(盲肠炎)”](https://www.uptodate.cn/contents/zh-Hans/neutropenic-enterocolitis-typhlitis?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

多种其他肠道病原体也可引起腹泻，应予以排除。(参见下文[‘腹泻’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H12425073)和 [“资源丰富地区成人急性腹泻的处理方法”](https://www.uptodate.cn/contents/zh-Hans/approach-to-the-adult-with-acute-diarrhea-in-resource-rich-settings?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

肺炎 — 肺炎病因可分为感染性和非感染性。鉴别诊断受浸润类型的影响很大。肺部浸润可被分为结节性(或局限性)或弥漫性。

●**结节性病灶**–植活前的大部分结节性病灶由感染性病因所致[[29](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/29)]。细菌(G+和G-)和霉菌(相对少见)病原体占多数。

●**弥漫性浸润**–非感染性病因(如预处理引起的肺水肿或肺损伤)的弥漫性浸润在该阶段更为常见([表 4](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=PULM%2F83194&topicKey=ID%2F1403&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&rank=1%7E150&source=see_link))。但呼吸道病毒可能导致上呼吸道和下呼吸道感染，后者常表现为弥漫性或片状浸润。

值得注意的是，与植活同时出现的肺部浸润(一般为弥漫型)常为非感染性，是由于出血性肺泡炎或细胞因子驱动的炎症反应(即植入综合征)。据报道，7%-10%自体HCT受者可出现植入综合征，但在异基因HCT受者中相对少见。(参见 [“自体造血干细胞移植后的肺部并发症”，关于‘植入综合征和PERDS’一节](https://www.uptodate.cn/contents/zh-Hans/pulmonary-complications-after-autologous-hematopoietic-cell-transplantation?sectionName=%E6%A4%8D%E5%85%A5%E7%BB%BC%E5%90%88%E5%BE%81%E5%92%8CPERDS&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H15960344&source=see_link#H15960344)和 [“异基因造血干细胞移植后的肺部并发症病因”，关于‘植入综合征’一节](https://www.uptodate.cn/contents/zh-Hans/pulmonary-complications-after-allogeneic-hematopoietic-cell-transplantation-causes?sectionName=%E6%A4%8D%E5%85%A5%E7%BB%BC%E5%90%88%E5%BE%81&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H6458592&source=see_link#H6458592))

血管导管相关性蜂窝织炎 — 插管部位或者沿导管皮下路径出现红斑、疼痛、肿胀和/或压痛，是血管导管相关性蜂窝织炎的常见临床表现。导管出口部位分泌物培养或者血流采样培养可能有用，应做该检测，但结果常呈阴性；因此，可以根据最可能的致病菌，选择相应药物进行假设性治疗。鉴于可能发生菌血症，还应开展血培养。至少半数致病菌为葡萄球菌，特别是表皮葡萄球菌(_Staphylococcus epidermidis_)。评估和处理详见其他专题。(参见 [“Intravascular catheter-related infection: Epidemiology, pathogenesis, and microbiology”](https://www.uptodate.cn/contents/intravascular-catheter-related-infection-epidemiology-pathogenesis-and-microbiology?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“血管内非血液透析导管相关感染的治疗”](https://www.uptodate.cn/contents/zh-Hans/intravascular-non-hemodialysis-catheter-related-infection-treatment?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

血流感染 — HCT受者常有血流感染，一般与中心静脉导管或者黏膜损伤有关。G+菌[表皮葡萄球菌、金黄色葡萄球菌(_Staphylococcus aureus_)]感染最常见，但也会发生G-菌和假丝酵母菌血流感染。除中心静脉导管外，可能的感染源还包括消化道和(对于细菌性感染)肺部。(参见 [“中性粒细胞减少性发热综合征的概述”，关于‘细菌性病原体’一节](https://www.uptodate.cn/contents/zh-Hans/overview-of-neutropenic-fever-syndromes?sectionName=%E7%BB%86%E8%8F%8C%E6%80%A7%E7%97%85%E5%8E%9F%E4%BD%93&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H9533710&source=see_link#H9533710)和 [“中性粒细胞减少性发热综合征的概述”，关于‘真菌性病原体’一节](https://www.uptodate.cn/contents/zh-Hans/overview-of-neutropenic-fever-syndromes?sectionName=%E7%9C%9F%E8%8F%8C%E6%80%A7%E7%97%85%E5%8E%9F%E4%BD%93&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H9533717&source=see_link#H9533717)和 [“Intravascular catheter-related infection: Epidemiology, pathogenesis, and microbiology”](https://www.uptodate.cn/contents/intravascular-catheter-related-infection-epidemiology-pathogenesis-and-microbiology?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“成人假丝酵母菌菌血症和侵袭性假丝酵母菌病的临床表现与诊断”](https://www.uptodate.cn/contents/zh-Hans/clinical-manifestations-and-diagnosis-of-candidemia-and-invasive-candidiasis-in-adults?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

肝炎 — 此阶段感染性肝细胞损伤少见。肝窦阻塞综合征(sinusoidal obstruction syndrome, SOS；旧称小静脉闭塞病)一般在植活前阶段首次出现，很少在移植第30日后发病。偶发急性胆囊炎，胆汁淤积相关综合征患者应考虑这种情况。(参见 [“成人肝窦阻塞综合征(肝小静脉闭塞病)”](https://www.uptodate.cn/contents/zh-Hans/hepatic-sinusoidal-obstruction-syndrome-veno-occlusive-disease-in-adults?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in children”](https://www.uptodate.cn/contents/hepatic-sinusoidal-obstruction-syndrome-veno-occlusive-disease-in-children?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

出血性膀胱炎 — 植活前出血性膀胱炎通常由预处理方案的膀胱黏膜毒性导致，如[环磷酰胺](https://www.uptodate.cn/contents/zh-Hans/92845?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)、[异环磷酰胺](https://www.uptodate.cn/contents/zh-Hans/92842?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)、[白消安](https://www.uptodate.cn/contents/zh-Hans/92846?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和全身放疗[[30,31](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/30,31)]。相比之下，植活后出血性膀胱炎常由病毒引起，如BK多瘤病毒(BK polyomavirus, BKPyV)或腺病毒。(参见下文[‘出血性膀胱炎’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H12425433))

植活后早期植活后早期(HCT后第30-100日)发生感染的主要危险因素为急性GVHD及其治疗、未完全治愈的黏膜炎和皮肤损伤(与植活前类似)，以及复发性或持续性中性粒细胞减少([图 2](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=ID%2F52716&topicKey=ID%2F1403&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&rank=1%7E150&source=see_link)和[图 3](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=ID%2F64491&topicKey=ID%2F1403&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&rank=1%7E150&source=see_link))[[32](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/32)]_。_多种病原体均可在此阶段引起感染。

肺炎 — 肺炎是常见的植活后早期并发症。与植活前一样，影像学特征(结节性 vs 弥漫性)在鉴别诊断中发挥重要作用。

●**结节性病灶**–结节性肺炎最可能为感染性，其中细菌(G+和G-)和霉菌感染最多见[[29](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/29)]。

与植活前不同，侵袭性曲霉菌病(较少见情况下为其他霉菌病)是结节性浸润更为常见的病因，造成了40%-50%的结节性肺炎并需要积极治疗，因此推荐诊断性评估[[29](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/29)]。异基因和自体HCT受者均可发生侵袭性曲霉菌病，不过异基因受者中更多见(5%-30% vs 1%-5%)[[33-36](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/33-36)]。(参见 [“侵袭性曲霉菌病的流行病学和临床表现”](https://www.uptodate.cn/contents/zh-Hans/epidemiology-and-clinical-manifestations-of-invasive-aspergillosis?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

尽管识别出多种植活后侵袭性曲霉菌病的危险因素，但最为主要的是急性和慢性GVHD以及CMV病[[37](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/37)]。约90%的肺部真菌感染是曲霉菌所致。但在HCT受者中，不太常见但可能致死的机会性真菌病越来越多见，致病菌包括：毛霉病的致病菌(占肺部真菌感染的5%-10%)，以及不太常见情况下的镰刀菌、尖端赛多孢子菌(_Scedosporium apiospermum_)复合体等[[33,38](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/33,38)]。这些感染的临床特征往往与曲霉菌病类似，不过镰刀菌也有一些独特的表现，包括皮损和血流感染[[38,39](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/38,39)]。(参见 [“镰刀菌感染的临床表现与诊断”](https://www.uptodate.cn/contents/zh-Hans/clinical-manifestations-and-diagnosis-of-fusarium-infection?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“毛霉菌病(接合菌病)”](https://www.uptodate.cn/contents/zh-Hans/mucormycosis-zygomycosis?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“赛多孢子菌和节荚孢霉感染的流行病学、临床表现和诊断”](https://www.uptodate.cn/contents/zh-Hans/epidemiology-clinical-manifestations-and-diagnosis-of-scedosporium-and-lomentospora-infections?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

●**弥漫性浸润**–对于弥漫性浸润，与植活前相比，植活后早期感染性病因要常见得多([表 5](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=PULM%2F83195&topicKey=ID%2F1403&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&rank=1%7E150&source=see_link))。CMV、呼吸道病毒和肺孢子菌肺炎(_Pneumocystis_ pneumonia, PCP)是较常见的病因，但很少在植活前出现。预处理方案毒性引起的特发性肺炎也是此阶段弥漫性浸润的常见原因，特别是对接受清髓性预处理的异基因HCT受者。(参见 [“异基因造血干细胞移植后的肺部并发症病因”，关于‘特发性肺炎综合征’一节](https://www.uptodate.cn/contents/zh-Hans/pulmonary-complications-after-allogeneic-hematopoietic-cell-transplantation-causes?sectionName=%E7%89%B9%E5%8F%91%E6%80%A7%E8%82%BA%E7%82%8E%E7%BB%BC%E5%90%88%E5%BE%81&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H17&source=see_link#H17))

需要重点考虑的肺炎特定病因包括：

●**_肺孢子菌_**–在接受复方磺胺甲噁唑(trimethoprim-sulfamethoxazole, TMP-SMX)预防治疗的HCT受者中，PCP不常见(<1%)[[40-43](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/40-43)]。对于存在高热、干咳、低氧血症和间质肺炎的患者，应考虑PCP诊断的情况包括：存在风险但未接受预防性治疗；所用的药物并不合适(喷他脒喷雾，或[氨苯砜](https://www.uptodate.cn/contents/zh-Hans/92285?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)隔日1次)；或者未依从预防性方案。据报道，与使用TMP-SMX相比，一周3次氨苯砜治疗时的PCP风险显著更高(7.2% vs 0.37%)[[42](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/42)]，但氨苯砜每日给药的患者则不然。氨苯砜每日给药时的PCP预防效果与仍可TMP-SMX预防时相似[[44](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/44)]。喷他脒喷雾预防治疗的效果不如TMP-SMX或每日给予氨苯砜[[45](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/45)]。PCP的危险因素包括：长期使用免疫抑制剂(高剂量糖皮质激素)、慢性GVHD、使用嘌呤类似物或者[利妥昔单抗](https://www.uptodate.cn/contents/zh-Hans/92827?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)、CD4+T细胞计数<200/μL以及血液系统恶性肿瘤复发[[40](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/40)]。(参见 [“造血干细胞移植受者感染的预防”，关于‘针对肺孢子菌的预防性治疗’一节](https://www.uptodate.cn/contents/zh-Hans/prevention-of-infections-in-hematopoietic-cell-transplant-recipients?sectionName=%E9%92%88%E5%AF%B9%E8%82%BA%E5%AD%A2%E5%AD%90%E8%8F%8C%E7%9A%84%E9%A2%84%E9%98%B2%E6%80%A7%E6%B2%BB%E7%96%97&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H29&source=see_link#H29))

●**呼吸道病毒**–呼吸道病毒可能导致上呼吸道和下呼吸道感染，后者的影像学检查通常表现为弥漫性或片状浸润。值得注意的是，在没有临床疾病的情况下，也可能发生长期无症状性病毒排出，并可能检出共存病原体，如CMV、曲霉菌或耶氏肺孢子菌(_Pneumocystis jirovecii_)。这些共存病原体可引起或促使发生下呼吸道疾病，需要治疗[[46-49](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/46-49)]。**严重急性呼吸综合征冠状病毒2型(severe acute respiratory syndrome coronavirus 2, SARS-CoV-2)为2019冠状病毒病(coronavirus disease 2019, COVID-19)的致病病毒，属于可在HCT后导致肺炎的呼吸道感染病毒。癌症和免疫功能受损或低下患者的风险可能高于健康个体，但尚未充分研究。** (参见 [“2019冠状病毒病(COVID-19)：流行病学、病毒学和预防”](https://www.uptodate.cn/contents/zh-Hans/covid-19-epidemiology-virology-and-prevention?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“COVID-19的临床特征”](https://www.uptodate.cn/contents/zh-Hans/covid-19-clinical-features?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“2019冠状病毒病(COVID-19)的诊断”](https://www.uptodate.cn/contents/zh-Hans/covid-19-diagnosis?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

●**CMV**–常规使用预防性或抢先性抗CMV治疗方案前，70%-80%的CMV血清学阳性异基因HCT受者可发生CMV再激活，其中1/3可能发生CMV病，主要为肺炎[[50](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/50)]。相比之下，仅40%的自体或同基因HCT受者发生CMV再激活，其中仅不到5%发生CMV病(主要为肺炎)[[51-53](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/51-53)]。

目前CMV肺炎并不常见，异基因HCT受者中发生率<5%。但鉴于其可以治疗，不治疗的话可能致死，在肺炎评估时，应进行检测，排除CMV导致弥漫性肺炎的可能性。CMV再激活和CMV病的主要危险因素包括：GVHD、使用高剂量糖皮质激素，以及既往CMV病毒血症。HCT受者的CMV预防详见其他专题。(参见 [“造血干细胞移植受者的病毒感染预防”，关于‘巨细胞病毒’一节](https://www.uptodate.cn/contents/zh-Hans/prevention-of-viral-infections-in-hematopoietic-cell-transplant-recipients?sectionName=%E5%B7%A8%E7%BB%86%E8%83%9E%E7%97%85%E6%AF%92&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H1058289551&source=see_link#H1058289551))

●**播散性类圆线虫病**–在极少HCT受者中曾报道过一种快速致死性高度感染综合征，表现为播散性类圆线虫病和急性呼吸窘迫综合征[[54,55](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/54,55)]。该感染可发生于皮肤接触受污染的土壤后。

●**播散性弓形虫病**–播散性弓形虫病罕见，但常有肺部受累，影像学检查通常表现为弥漫性浸润[[56,57](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/56,57)]。

腹泻 — 植活后早期出现腹泻的原因不一，可分为感染性原因及非感染性，见下文：

●**急性GVHD**–植活后早期，急性GVHD是最重要和常见的腹泻原因。胃肠道GVHD引起的腹泻常伴有GVHD的其他表现，尤其是皮疹，但也可能无其他器官受累。因此需要通过下消化道内镜活检来充分评估这一点。(参见 [“急性移植物抗宿主病的临床表现、诊断和分级”](https://www.uptodate.cn/contents/zh-Hans/clinical-manifestations-diagnosis-and-grading-of-acute-graft-versus-host-disease?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

●**CMV结肠炎**–CMV结肠炎也是一个需要结肠活检来评估的重要问题。CMV结肠炎可单独发作或伴发胃肠道GVHD。标本活检时这两样都要检查。

●**药物**–在该阶段，药物是常见的腹泻原因。HCT后腹泻的常见致病药物是口服镁剂，其用于治疗钙调磷酸酶抑制剂常引起的低镁血症。

●**_艰难梭菌_**–一项重要发现是，该人群中发生的艰难梭菌感染(_C. difficile_ infection, CDI)通常没有典型的临床表现，包括黏膜假膜和白细胞计数升高[[27,58-60](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/27,58-60)]。同样，与其他住院患者相比，这类患者的直接并发症(如需要手术切除的穿孔)发病率相对较低[[27](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/27)]。但据报道，CDI与胃肠道GVHD有显著相关性[[27,60](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/27,60)]。

●**腺病毒**–HCT后可能会出现腺病毒再激活或新发获得性感染。HCT后常见腺病毒再激活感染，但很少引起严重疾病[[61](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/61)]。腺病毒感染可能无症状(仅为病毒血症)或者发展成为不同的综合征，包括：上呼吸道感染、重症肺炎、腹泻和出血性结肠炎、肾炎和/或出血性膀胱炎。较少见的表现包括：心肌炎、肝炎[[62](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/62)]、脑炎，以及播散性疾病伴多器官功能衰竭。不过播散性疾病罕见，见于1%-7%的病例，死亡率为8%-26%[[61](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/61)]。腺病毒疾病发生发展与腺病毒特异性T细胞缺乏有关。腺病毒感染的危险因素包括：需使用大剂量糖皮质激素治疗的严重GVHD[[63,64](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/63,64)]、T细胞去除[[65,66](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/65,66)]、使用阿伦单抗或ATG[[67](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/67)]，以及使用非亲缘相合移植物、半相合移植物或者脐血[[61](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/61)]。儿童比成人更易发生腺病毒感染[[68](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/68)]。(参见 [“腺病毒感染的发病机制、流行病学和临床表现”，关于‘造血干细胞移植’一节](https://www.uptodate.cn/contents/zh-Hans/pathogenesis-epidemiology-and-clinical-manifestations-of-adenovirus-infection?sectionName=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H23&source=see_link#H23))

●**肠道病原体**–HCT受者感染肠道病毒可导致胃肠炎(柯萨奇A组病毒[[69](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/69)]、轮状病毒、诺如病毒[[70,71](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/70,71)])，这可能会持续很长时间并引起严重腹泻[[72](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/72)]，但也可能累及其他器官系统，包括肺、心血管系统及中枢神经系统。淋巴细胞减少是这些肠道感染的一个诱发因素[[72](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/72)]。感染通常通过粪-口途径传播。肠道系统的病毒感染(如柯萨奇病毒、埃可病毒和轮状病毒)在夏秋季高发，但轮状病毒感染也在冬春季发病[[72](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/72)]。在异基因去T细胞骨髓移植、CD34阳性特定自体HCT、T细胞去除或强化免疫抑制治疗GVHD后，有极少量小隐孢子虫(_Cryptosporidium parvum_)引起胃肠炎的报道。这种感染可能与肠道GVHD类似[[73,74](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/73,74)]。(参见 [“Cryptosporidiosis: Epidemiology, clinical manifestations, and diagnosis”](https://www.uptodate.cn/contents/cryptosporidiosis-epidemiology-clinical-manifestations-and-diagnosis?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“诺如病毒”](https://www.uptodate.cn/contents/zh-Hans/norovirus?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

肝炎 — 肝脏异常有很多潜在原因，包括：药物毒性、急性GVHD、铁过载、肝炎病毒感染、其他病毒感染[如CMV、EB病毒、人疱疹病毒6型(human herpesvirus 6, HHV-6)、腺病毒]，以及慢性播散性假丝酵母菌病(肝脾假丝酵母菌病)。SOS(旧称小静脉闭塞病)一般在植活前首次出现，很少在第30日后发病。(参见 [“成人肝窦阻塞综合征(肝小静脉闭塞病)”](https://www.uptodate.cn/contents/zh-Hans/hepatic-sinusoidal-obstruction-syndrome-veno-occlusive-disease-in-adults?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

该时期发生的肝脏并发症主要考虑是GVHD。GVHD通常倾向于表现为胆汁淤积型而非肝细胞损伤型，但会有不少重叠。肝脏活检可帮助明确诊断。若存在完整的典型急性GVHD表现(特征性皮疹、胆红素升高和腹泻)，对最易取样的受累部位进行活检可能足以明确诊断，从而避免肝脏活检，尽量降低活检并发症风险。

由于HBsAg(-)患者中可能持续存在乙型肝炎病毒(hepatitis B virus, HBV)隐匿性感染，在HCT后，HBV可再激活。强化免疫抑制可能使一些HBsAb(+)和HBcAb(+)患者血清转化为HBsAg(+)状态，淋巴瘤患者尤其如此[[75](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/75)]。韩国一项研究显示，129例HBsAg(-)自体HCT患者中，有7(6%)例血清转化为HBsAg(+)状态，5例(4%)发生急性肝炎[[76](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/76)]。多发性骨髓瘤也可增加自体HCT后HBV再激活的风险[[77,78](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/77,78)]，有研究提示抗骨髓瘤活性的免疫调节药物([沙利度胺](https://www.uptodate.cn/contents/zh-Hans/92286?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)、[硼替佐米](https://www.uptodate.cn/contents/zh-Hans/94061?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))可能也会增加此风险[[78](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/78)]。

HBV感染的血清学特征可能会因严重的免疫抑制而改变，该免疫抑制可影响HBV感染的体液和细胞免疫控制；部分HBsAg(+)患者可能不出现HBcAb，即使是高水平的HBV复制或HBcAb(+)移植物受者。

免疫重建后的急性肝炎是最常见的表现(约60%)，尤其是在免疫抑制逐渐减弱时，不过高达20%的患者可能不会出现任何肝脏病变体征和症状。可能长期存在氨基转移酶升高。1/4病例中，再激活可能会自发性缓解，而暴发性肝炎极其罕见。

GVHD是病毒性肝炎的重要鉴别诊断，因为推定诊断的肝脏GVHD所用糖皮质激素治疗可能会缓解这两种情况的症状，但若实为病毒性肝炎，却会导致病毒复制增加和延误有效的抗病毒治疗。可能需要肝脏活检来确诊GVHD。

随着免疫重建，HBV病毒载量显著增加者可表现为急性肝炎。若肝酶增至≥10倍正常上限，则需糖皮质激素治疗[[79](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/79)]。这种免疫“爆发”可能出现在该阶段或者HCT后更晚阶段。

>50%的异基因HCT受者发生丙型肝炎病毒(hepatitis C virus, HCV)再激活。HCV病毒血症(HCV RNA阳性)和HCT前肝功能检测发现肝酶升高的患者发生严重围移植期并发症的风险较高。HCV血清学阳性是异基因HCT后非复发死亡的危险因素，即使是肝功能检测正常的患者[[80,81](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/80,81)]，且与植入后早期出现一过性肝炎有关；HCV也是SOS和早期肝硬化的危险因素[[81,82](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/81,82)]。但一项研究显示，HCV感染对10年生存率无负面影响[[83](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/83)]。HCV再激活可能表现为急性肝炎伴HCV病毒载量显著增加，有可能致死[[79](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/79)]。

HCT后HBV和HCV相关性疾病的预防详见其他专题。(参见 [“造血干细胞移植受者的病毒感染预防”，关于‘乙型肝炎病毒’一节](https://www.uptodate.cn/contents/zh-Hans/prevention-of-viral-infections-in-hematopoietic-cell-transplant-recipients?sectionName=%E4%B9%99%E5%9E%8B%E8%82%9D%E7%82%8E%E7%97%85%E6%AF%92&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H1058289659&source=see_link#H1058289659)和 [“造血干细胞移植受者的病毒感染预防”，关于‘丙型肝炎病毒’一节](https://www.uptodate.cn/contents/zh-Hans/prevention-of-viral-infections-in-hematopoietic-cell-transplant-recipients?sectionName=%E4%B8%99%E5%9E%8B%E8%82%9D%E7%82%8E%E7%97%85%E6%AF%92&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H1058289691&source=see_link#H1058289691))

肝炎的其他潜在病因见下文。(参见下文[‘肝炎’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H12425583))

出血性膀胱炎 — BK多瘤病毒是植活后早期发生出血性膀胱炎的常见原因，而腺病毒则是较少见的病因，更甚少见的原因包括：其他感染[如，CMV、JC多瘤病毒(JC polyomavirus, JCPyV)]、血液系统疾病(出血性疾病、血小板减少症)，以及预处理相关性损伤[[31,64,84,85](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/31,64,84,85)]。(参见 [“腺病毒感染的发病机制、流行病学和临床表现”，关于‘泌尿生殖道’一节](https://www.uptodate.cn/contents/zh-Hans/pathogenesis-epidemiology-and-clinical-manifestations-of-adenovirus-infection?sectionName=%E6%B3%8C%E5%B0%BF%E7%94%9F%E6%AE%96%E9%81%93&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H17&source=see_link#H17))

BKPyV诱发的出血性膀胱炎最常见于HCT后3-6周[[30,86](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/30,86)]。预处理方案毒性导致的出血性膀胱炎通常发生于植活前阶段。(参见上文[‘出血性膀胱炎’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H258911))

BKPyV可持续感染肾小管上皮细胞，也可在尿路上皮细胞中复制。BKPyV相关性出血性膀胱炎危险因素包括：HLA不相合患者接受清髓性预处理，尤其是移植物来源于非亲缘供者或者脐血HCT受者[[87,88](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/87,88)]。据报道，使用阿仑单抗预处理也属于危险因素[[89](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/89)]。一项研究阐明了BKPyV复制、预处理强度和供者类型间的复杂相互作用。该研究显示，与所有其他受者相比，移植前PCR示尿BKPyV阳性且使用清髓性预处理的半相合移植物或脐血移植物受者发生出血性膀胱炎的风险显著更高(58% vs 7%)[[88](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/88)]。GVHD可能是出血性膀胱炎的危险因素，但尚未明确[[87,88](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/87,88)]。

BK病毒尿(尿中检出BKPyV复制)可见于近半数的异基因和不足10%的自体HCT受者，与出血性膀胱炎有关[[84,86,90-92](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/84,86,90-92)]。但检出BK病毒尿不足以诊断BKPyV相关性出血性膀胱炎。HCT受者在血浆中检出BKPyV DNA也是BKPyV相关性出血性膀胱炎的标志物。有研究者认为，BK病毒血症水平>10,000拷贝/mL可预测HCT受者的肾脏和泌尿道结局[[93](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/93)]。一项病例对照研究比较了30例证实BK病毒尿的出血性膀胱炎患者与匹配对照者，通过PCR每周检测血浆样本的BKPyV DNA情况[[92](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/92)]。发病前或者发病期间检出BK病毒血症与出血性膀胱炎独立相关。BKPyV相关性出血性膀胱炎患者的血浆BK病毒载量峰值显著更高，BK病毒血症持续时间较长。(参见 [“Overview and virology of JC polyomavirus, BK polyomavirus, and other polyomavirus infections”, section on ‘Hemorrhagic cystitis’](https://www.uptodate.cn/contents/overview-and-virology-of-jc-polyomavirus-bk-polyomavirus-and-other-polyomavirus-infections?sectionName=Hemorrhagic+cystitis&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H2560659090&source=see_link#H2560659090))

HCT后BKPyV相关性出血性膀胱炎的临床表现严重程度不一，可能包括：膀胱炎(尿痛、尿急、下腹部不适)、伴或不伴血凝块的肉眼血尿、梗阻引起的肾衰竭，罕见情况下还发生需要泌尿系统干预(包括膀胱切除术)的危及生命的出血。

HCT受者中有少量关于BKPyV引起输尿管狭窄的报道[[94,95](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/94,95)]。一项报告显示，一例感染BKPyV的HCT受者发生了出血性膀胱炎后，出现了双侧输尿管狭窄，这表明BKPyV可导致上行感染[[94](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/94)]。偶有病例活检证实，BKPyV病毒尿的肾衰竭风险较高[[96](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/96)]。

脑炎 — 几种病原体可导致脑炎，尤其是病毒(如，HHV-6)，其他病原体包括刚地弓形虫(_Toxoplasma gondii_)等：

●**HHV-6**–HHV-6再激活可见于30%-50%的异基因HCT受者[[97-100](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/97-100)]，其中仅少部分会发生脑炎。HHV-6再激活常表现为HHV-6病毒血症，一般发生在移植后2-4周。移植受者中的HHV-6感染详见其他专题。(参见 [“Human herpesvirus 6 infection in hematopoietic cell transplant recipients”](https://www.uptodate.cn/contents/human-herpesvirus-6-infection-in-hematopoietic-cell-transplant-recipients?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

●**HSV**–患者出现脑炎时应考虑HSV感染[[101,102](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/101,102)]，不过如今这种情况很少见。[阿昔洛韦](https://www.uptodate.cn/contents/zh-Hans/94044?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)或[伐昔洛韦](https://www.uptodate.cn/contents/zh-Hans/92360?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)预防治疗通常可避免HSV再激活，但停止抗病毒预防或感染耐药株时，可发生HSV再激活。(参见 [“单纯疱疹病毒1型脑炎”](https://www.uptodate.cn/contents/zh-Hans/herpes-simplex-virus-type-1-encephalitis?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“带状疱疹的流行病学、临床表现和诊断”](https://www.uptodate.cn/contents/zh-Hans/epidemiology-clinical-manifestations-and-diagnosis-of-herpes-zoster?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“造血干细胞移植受者的病毒感染预防”，关于‘单纯疱疹病毒’一节](https://www.uptodate.cn/contents/zh-Hans/prevention-of-viral-infections-in-hematopoietic-cell-transplant-recipients?sectionName=%E5%8D%95%E7%BA%AF%E7%96%B1%E7%96%B9%E7%97%85%E6%AF%92&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H1058289478&source=see_link#H1058289478)和 [“造血干细胞移植受者的病毒感染预防”，关于‘水痘-带状疱疹病毒’一节](https://www.uptodate.cn/contents/zh-Hans/prevention-of-viral-infections-in-hematopoietic-cell-transplant-recipients?sectionName=%E6%B0%B4%E7%97%98-%E5%B8%A6%E7%8A%B6%E7%96%B1%E7%96%B9%E7%97%85%E6%AF%92&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H1058289500&source=see_link#H1058289500))

●**VZV**–VZV再激活通常发生在植活后晚期，但在患者出现脑炎时，即使是植活后早期，仍应考虑该情况。(参见下文[‘脑炎和脑膜炎’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H12425623)和 [“造血干细胞移植受者的病毒感染预防”，关于‘水痘-带状疱疹病毒’一节](https://www.uptodate.cn/contents/zh-Hans/prevention-of-viral-infections-in-hematopoietic-cell-transplant-recipients?sectionName=%E6%B0%B4%E7%97%98-%E5%B8%A6%E7%8A%B6%E7%96%B1%E7%96%B9%E7%97%85%E6%AF%92&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H1058289500&source=see_link#H1058289500)和 [“带状疱疹的流行病学、临床表现和诊断”，关于‘脑炎’一节](https://www.uptodate.cn/contents/zh-Hans/epidemiology-clinical-manifestations-and-diagnosis-of-herpes-zoster?sectionName=%E8%84%91%E7%82%8E&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H2616240095&source=see_link#H2616240095))

●**CMV**–HCT受者中很少有CMV导致脑炎的报道[[101,103,104](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/101,103,104)]。中枢神经系统CMV病的危险因素包括：长时间重度T细胞免疫缺陷(T细胞去除、ATG、脐血移植)、多疗程抢先抗病毒疗法治疗复发性CMV病毒血症史，以及[更昔洛韦](https://www.uptodate.cn/contents/zh-Hans/94041?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)耐药性CMV感染[[103](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/103)]。(参见 [“造血干细胞移植受者的病毒感染预防”，关于‘巨细胞病毒’一节](https://www.uptodate.cn/contents/zh-Hans/prevention-of-viral-infections-in-hematopoietic-cell-transplant-recipients?sectionName=%E5%B7%A8%E7%BB%86%E8%83%9E%E7%97%85%E6%AF%92&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H1058289551&source=see_link#H1058289551))

●**EB病毒**–EB病毒感染最常发生于植活后晚期，不过在接受去T细胞HCT或抗T细胞单克隆抗体(如阿仑单抗)治疗的受者中，可在第100日前检出感染[[105](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/105)]。移植后淋巴增殖性疾病(post-transplant lymphoproliferative disorder, PTLD)可表现为发热、淋巴结肿大和/或多种器官结外淋巴瘤性增殖(肝、消化道、肺、中枢神经系统和骨髓)，其特征为单克隆B细胞增殖伴恶性细胞遗传学异常以及免疫球蛋白基因重排。(参见 [“移植后淋巴增殖性疾病的流行病学、临床表现和诊断”](https://www.uptodate.cn/contents/zh-Hans/epidemiology-clinical-manifestations-and-diagnosis-of-post-transplant-lymphoproliferative-disorders?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

●**JCPyV**–JCPyV可在中枢神经系统复制，从而导致此处严重的皮质下区域脱髓鞘[即，进行性多灶性白质脑病(progressive multifocal leukoencephalopathy, PML)]或小脑脱髓鞘(即，颗粒细胞神经元神经病)。PML常表现为亚急性神经功能障碍，包括：癫痫发作、神志改变、视野缺失相关的视觉症状(偏盲和复视)、无力、轻偏瘫或单肢轻瘫和/或共济失调[[106](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/106)]。当神经影像学检查示多灶性病变局限于脑白质、无明显对比增强、无占位效应且与血管分布不一致时，应考虑PML。虽然脑活检是诊断PML的金标准，但会引起严重并发症甚至死亡。大多数情况下，对于存在特征性神经系统或者神经影像学表现的患者，通过PCR检测脑脊液JCPyV DNA可实验室确诊[[107](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/107)]。HCT后出现PML首发症状的中位时间为11个月，症状出现后的中位生存时间约20个月[[108](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/108)]。HCT受者发生PML的危险因素包括：[氟达拉滨](https://www.uptodate.cn/contents/zh-Hans/92797?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)[[109,110](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/109,110)]或[利妥昔单抗](https://www.uptodate.cn/contents/zh-Hans/92827?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)[[111,112](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/111,112)]治疗，CD4+T细胞数极低的患者尤其如此[[112](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/112)]。PML详见其他专题。(参见 [“进行性多灶性白质脑病的流行病学、临床表现和诊断”](https://www.uptodate.cn/contents/zh-Hans/progressive-multifocal-leukoencephalopathy-pml-epidemiology-clinical-manifestations-and-diagnosis?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

●**西尼罗河病毒**–HCT受者中有过西尼罗河病毒感染，在夏末和秋季发病[[113,114](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/113,114)]。传播途径为蚊叮咬(中位潜伏期2周)，极少数通过输血或受感染的移植物传播(输血或接受移植物后4周内)。HCT受者中，西尼罗河病毒感染表现包括：发热、嗜睡，以及快速进展性双侧肢体无力导致急性弛缓性麻痹(严重四肢轻瘫或者四肢瘫，伴肌张力低下和反射消失)。HCT受者感染西尼罗河病毒的其他表现包括脑膜炎和/或脑炎。大部分患者都发生脑病。通过临床表现+在血液、组织或脑脊液样本中检出西尼罗河病毒诊断，病毒检测方法是PCR，极少数情况下采用病毒培养[[114](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/114)]。HCT受者存在严重的免疫缺陷，因此脑脊液西尼罗河病毒IgM抗体检测的敏感性并不高[[114](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/114)]。西尼罗河病毒详见其他专题。(参见 [“Epidemiology and pathogenesis of West Nile virus infection”](https://www.uptodate.cn/contents/epidemiology-and-pathogenesis-of-west-nile-virus-infection?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“西尼罗病毒感染的临床表现及诊断”](https://www.uptodate.cn/contents/zh-Hans/clinical-manifestations-and-diagnosis-of-west-nile-virus-infection?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

●**腺病毒**–腺病毒是HCT受者发生脑炎的罕见原因[[102](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/102)]。(参见上文[‘腹泻’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H12425073)和 [“腺病毒感染的发病机制、流行病学和临床表现”，关于‘神经系统’一节](https://www.uptodate.cn/contents/zh-Hans/pathogenesis-epidemiology-and-clinical-manifestations-of-adenovirus-infection?sectionName=%E7%A5%9E%E7%BB%8F%E7%B3%BB%E7%BB%9F&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H18&source=see_link#H18))

●**弓形虫病**–脑弓形虫病通常发生在异基因HCT后第60-150日，可能表现为颅内压增高、神经功能障碍和/或癫痫发作，这些均由颅内脓肿引起，后者可通过脑MRI识别。HCT受者发生弓形虫病的其他表现包括：吉兰-巴雷综合征、皮肤感染、血液系统并发症(如移植失败[[115](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/115)]或噬血细胞综合征[[116](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/116)])、脉络膜视网膜炎[[117](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/117)]或播散性疾病[[56](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/56)]。危险因素包括：血清学阳性、未预防性使用TMP-SMX、重度GVHD、清髓性预处理、T细胞去除或者使用ATG[[118-121](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/118-121)]。

病毒性脑炎(包括上文未提及的病因，如东部马脑炎病毒和其他虫媒病毒)详见其他专题。(参见 [“成人病毒性脑炎”](https://www.uptodate.cn/contents/zh-Hans/viral-encephalitis-in-adults?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“儿童急性病毒性脑炎的临床表现和诊断”](https://www.uptodate.cn/contents/zh-Hans/acute-viral-encephalitis-in-children-clinical-manifestations-and-diagnosis?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

除感染性原因外，以下非感染性原因也可引起脑病：

●[氟达拉滨](https://www.uptodate.cn/contents/zh-Hans/92797?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)毒性–氟达拉滨引起的迟发型皮质损伤可能会引起脑病，这可见于植活后早期或晚期，通常会逐渐进展。(参见 [“常规非铂类癌症化疗药物的神经系统并发症概述”，关于‘嘌呤类似物’一节](https://www.uptodate.cn/contents/zh-Hans/overview-of-neurologic-complications-of-conventional-non-platinum-cancer-chemotherapy?sectionName=%E5%98%8C%E5%91%A4%E7%B1%BB%E4%BC%BC%E7%89%A9&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H49&source=see_link#H49))

●**可逆性后部脑病综合征**–钙调磷酸酶抑制剂可引起可逆性后部脑病综合征(posterior reversible encephalopathy syndrome, PRES)[[122](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/122)]。PRES可表现为癫痫发作、神志改变、视觉症状或其他表现，可出现于植活后早期或晚期。(参见 [“可逆性后部白质脑病综合征”](https://www.uptodate.cn/contents/zh-Hans/reversible-posterior-leukoencephalopathy-syndrome?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

植活后晚期即使在移植后晚期，患者仍有很高的感染风险，因此可能需要长期随访。植活后晚期感染性并发症通常仅见于有特定危险因素的异基因HCT受者，包括[[123](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/123)]：

●广泛型慢性GVHD及GVHD的强化治疗，导致免疫重建延迟(如，细胞和体液免疫功能紊乱、脾功能减退症和调理作用下降)

●**CMV血清学阴性供者状态和CMV血清阳性受者状态(CMV D-/R+)**

●大剂量(清髓性)和基于放疗的预处理方案

在植活后晚期，鼻窦炎、上呼吸道感染、肺炎和脑膜炎通常由荚膜细菌[肺炎链球菌(_Streptococcus pneumoniae_)、流感嗜血杆菌(_Haemophilus influenzae_)、脑膜炎奈瑟菌(_Neisseria meningitidis_)]感染导致[[123-126](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/123-126)]。植入后晚期菌血症在异基因HCT后也常见，一般由荚膜细菌[[124-126](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/124-126)]、葡萄球菌以及G-菌[如，假单胞菌(_Pseudomonas_)]引起[[127](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/127)]。由于调理作用下降、低丙种球蛋白血症和脾功能减退，慢性GVHD患者尤其易发生感染。

一项纳入196例HLA相合亲缘HCT后的长期存活者(中位随访8年)的研究显示，30例存活不止1年的患者有19例死于感染[[123](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/123)]；30例患者发生了植入后晚期细菌感染(大部分为脓毒症和肺炎)，8年累积发病率为15%。识别出了18种病原体，包括肺炎链球菌(6例感染，其中3例为脑膜炎)、沙门菌(_Salmonella_；3例感染)、金黄色葡萄球菌(2例感染)、流感嗜血杆菌、艰难梭菌及其他。大部分感染发生在HCT后第2年，当时患者正接受[阿莫西林](https://www.uptodate.cn/contents/zh-Hans/92334?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)预防。患者根据欧洲的推荐接种了相关疫苗，其中包括肺炎链球菌疫苗[[128](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/128)]。广泛型慢性GVHD(HR 2.9)、CMV D-/R+血清学状态(HR 2.5)和基于照射的预处理方案(HR 3.1)是植入后晚期细菌感染的独立预测因子[[123](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/123)]。

肺炎 — 肺炎的感染性和非感染性病因大多与植活后早期的相似。弥漫性肺炎可分为非感染性[隐源性机化性肺炎(cryptogenic organizing pneumonia, COP)]和感染性(CMV、呼吸道病毒、PCP)，各占一半。结节性肺炎大多由感染引起，G+或G-菌最常见，偶由曲霉菌、其他霉菌或诺卡菌(_Nocardia_)引起。

●**闭塞性细支气管炎/闭塞性细支气管炎综合征和COP**–预处理方案毒性引起的特发性肺炎已不再是植活后晚期的主要问题。现在主要担心的是闭塞性细支气管炎/闭塞性细支气管炎综合征(bronchiolitis obliterans/bronchiolitis obliterans syndrome, BO/BOS)和COP[旧称闭塞性细支气管炎伴机化性肺炎(bronchiolitis obliterans with organizing pneumonia, BOOP)]，它们与慢性GVHD有关。BO和COP的临床表现为进行性呼吸困难和咳嗽，两者均有特征性影像学表现。有必要积极诊断和及时治疗，以减少进行性呼吸功能不全带来的威胁。若考虑这些诊断，应寻找感染，因为感染的表现可能与之相似，而且可能还会促使其发生。BO/BOS和COP详见其他专题。(参见 [“异基因造血干细胞移植后的肺部并发症病因”，关于‘气流阻塞与闭塞性细支气管炎’一节](https://www.uptodate.cn/contents/zh-Hans/pulmonary-complications-after-allogeneic-hematopoietic-cell-transplantation-causes?sectionName=%E6%B0%94%E6%B5%81%E9%98%BB%E5%A1%9E%E4%B8%8E%E9%97%AD%E5%A1%9E%E6%80%A7%E7%BB%86%E6%94%AF%E6%B0%94%E7%AE%A1%E7%82%8E&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H464750157&source=see_link#H464750157)和 [“成人细支气管疾病概述”](https://www.uptodate.cn/contents/zh-Hans/overview-of-bronchiolar-disorders-in-adults?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“异基因造血干细胞移植后的肺部并发症病因”，关于‘机化性肺炎’一节](https://www.uptodate.cn/contents/zh-Hans/pulmonary-complications-after-allogeneic-hematopoietic-cell-transplantation-causes?sectionName=%E6%9C%BA%E5%8C%96%E6%80%A7%E8%82%BA%E7%82%8E&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H193827199&source=see_link#H193827199)和 [“隐源性机化性肺炎”](https://www.uptodate.cn/contents/zh-Hans/cryptogenic-organizing-pneumonia?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

●**肺炎球菌**–对广泛型慢性GVHD进行治疗的患者有较高的肺炎球菌感染风险[[126,129](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/126,129)]，因为该类患者存在免疫球蛋白(通常为IgG2和IgG4亚型)缺乏[[130](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/130)]和脾功能减退症[[131,132](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/131,132)]。评估发生54次肺炎球菌感染的HCT受者(n=47)发现，有50次感染在较晚时间发生，平均为移植后473日[[126](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/126)]。菌血症性肺炎是最常见的表现，不过也有发生孤立性肺炎或菌血症。接种肺炎球菌疫苗后，仍有5例患者发生了感染。(参见 [“需住院治疗患者的肺炎球菌性肺炎”](https://www.uptodate.cn/contents/zh-Hans/pneumococcal-pneumonia-in-patients-requiring-hospitalization?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

●**CMV**–**随着抗CMV抢先疗法的应用，植活后晚期(移植第100日后)CMV感染和CMV病已成为异基因HCT后更重要的问题，且与非复发性死亡相关[[133](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/133)]。总体而言，分别有15%-30%和6%-18%异基因HCT受者发生植入后晚期CMV感染和CMV病[[133-136](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/133-136)]。植入后晚期CMV病的预测因素包括：CMV血清学阴性供者移植物、CMV特异性T细胞反应延迟或未重建(由于不相合/非亲缘移植)、采取抗CMV预防措施和/或早期CMV再激活(移植后第100日前)**[[133,136-138](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/133,136-138)]。(参见 [“造血干细胞移植受者的病毒感染预防”，关于‘巨细胞病毒’一节](https://www.uptodate.cn/contents/zh-Hans/prevention-of-viral-infections-in-hematopoietic-cell-transplant-recipients?sectionName=%E5%B7%A8%E7%BB%86%E8%83%9E%E7%97%85%E6%AF%92&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H1058289551&source=see_link#H1058289551))

●**诺卡菌**–诺卡菌可在此阶段引起结节性肺部浸润(有时还有皮肤结节和脑梗死)，难以与侵袭性肺曲霉病相鉴别[[139](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/139)]。(参见 [“诺卡菌病的临床表现和诊断”](https://www.uptodate.cn/contents/zh-Hans/clinical-manifestations-and-diagnosis-of-nocardiosis?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

●**真菌性肺炎**–真菌性肺炎的原因包括曲霉菌和毛霉病致病菌。在该阶段，真菌性肺炎最常见于使用糖皮质激素治疗GVHD的患者[[1,36](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/1,36)]。(参见 [“侵袭性曲霉菌病的流行病学和临床表现”](https://www.uptodate.cn/contents/zh-Hans/epidemiology-and-clinical-manifestations-of-invasive-aspergillosis?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“毛霉菌病(接合菌病)”](https://www.uptodate.cn/contents/zh-Hans/mucormycosis-zygomycosis?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

●**肺孢子菌**–植入后晚期PCP可能发生于不再使用TMP-SMX预防的患者[[40](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/40)]。该感染最常见于长期使用糖皮质激素治疗慢性GVHD的患者。(参见 [“非HIV感染者中肺孢子菌肺炎的流行病学、临床表现和诊断”](https://www.uptodate.cn/contents/zh-Hans/epidemiology-clinical-manifestations-and-diagnosis-of-pneumocystis-pneumonia-in-patients-without-hiv?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

●**PTLD**–EB病毒相关性PTLD可表现为肺部结节。至发病的中位时间是移植后3-5个月，不过有PTLD高风险的患者可在第100日前发生[[105](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/105)]。(参见 [“移植后淋巴增殖性疾病的流行病学、临床表现和诊断”](https://www.uptodate.cn/contents/zh-Hans/epidemiology-clinical-manifestations-and-diagnosis-of-post-transplant-lymphoproliferative-disorders?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

●**分枝杆菌**—移植受者很少有分枝杆菌感染，在异基因和自体HCT受者中发病率分别为1%-3%和0.2%[[140-144](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/140-144)]。感染原因可为再激活或者新暴露。结核病一般发生在植活后晚期(HCT第100日后，少数病例在HCT后4年才确诊)，表现为发热、咳嗽、体重减轻和不同类型的肺部浸润。肺外结核病可见于约15%的患者，受累部位可为肾脏、骨髓、中枢神经系统和关节[[145](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/145)]。

在发达国家，HCT受者较常感染的分枝杆菌是非结核分枝杆菌(nontuberculous mycobacteria, NTM)。感染NTM时，肺外结核病较为常见，如血流、导管相关性、软组织、骨和关节感染[[140-142](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/140-142)]。一项关于HCT受者中NTM感染的回顾性研究表明，发病率为0.4%-4.9%，至发病的中位时间为4.6个月[[146](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/146)]。GVHD是NTM感染的易感因素。

超过1/3的NTM病患者存在中心静脉导管相关性感染(菌血症、出口处或隧道感染)，其中大部分感染由快生长NTM[如，偶发分枝杆菌(_Mycobacterium fortuitum_)、脓肿分枝杆菌(_M. abscessus_)、龟分枝杆菌(_M. chelonae_)]引起[[146](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/146)]，快生长NTM感染一般可用常规血培养确诊。肺炎及播散性疾病常由鸟分枝杆菌(_Mycobacterium avium_)复合体或者嗜血分枝杆菌(_M. haemophilum_)引起，而皮损则见于嗜血分枝杆菌感染时，其还可引起播散性、骨关节性和导管相关性感染。(参见 [“非结核分枝杆菌感染的概述”](https://www.uptodate.cn/contents/zh-Hans/overview-of-nontuberculous-mycobacterial-infections?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“快速生长分枝杆菌感染：脓肿分枝杆菌、龟分枝杆菌和偶发分枝杆菌”](https://www.uptodate.cn/contents/zh-Hans/rapidly-growing-mycobacterial-infections-mycobacteria-abscessus-chelonae-and-fortuitum?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

肝炎 — 此阶段肝脏异常可由多种原因导致，与植活后早期相似，包括：药物毒性、慢性GVHD、铁过载、肝炎病毒、其他病毒(如CMV、EB病毒、HHV-6、腺病毒)和慢性播散性假丝酵母菌病(肝脾假丝酵母菌病)。随着免疫抑制方案逐渐减量，免疫逐步重建，可能出现肝炎病毒再激活引起的肝损伤。(参见上文[‘肝炎’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H12425087))

在HCT受者中，甲型、乙型、丙型和戊型肝炎病毒均可导致肝炎，且急性和慢性疾病均有报道[[147](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/147)]。(参见 [“戊型肝炎病毒感染”](https://www.uptodate.cn/contents/zh-Hans/hepatitis-e-virus-infection?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

在未接受[阿昔洛韦](https://www.uptodate.cn/contents/zh-Hans/94044?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)预防的患者中，不伴皮损的孤立性VZV再激活可累及到肝脏、胰腺或者肠壁浆膜，表现为严重的肝细胞损伤、腹痛或者肠梗阻[[148](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/148)]。这可导致严重的肝细胞损伤、肠穿孔或梗阻或者急腹症，当患者进行诊断评估时，应接受针对VZV的推测性治疗。

HSV也是肝炎的罕见病因之一。(参见 [“单纯疱疹病毒1型感染的流行病学、临床表现和诊断”，关于‘肝炎’一节](https://www.uptodate.cn/contents/zh-Hans/epidemiology-clinical-manifestations-and-diagnosis-of-herpes-simplex-virus-type-1-infection?sectionName=%E8%82%9D%E7%82%8E&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H22&source=see_link#H22))

皮损 — 慢性GVHD患者可出现各种皮疹和皮损。播散性真菌或细菌感染可引起皮肤和皮下结节。复发性HSV感染可引起唇部、生殖器溃疡和水疱。

VZV通常表现为水疱特征性皮节分布。异基因和自体HCT受者的VZV再激活发生率相近(20%-40%)。VZV感染往往更常见于儿童(不超过1岁者中高达90%)和移植后较早期(中位时间为HCT后第100日)[[149](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/149)]。一项研究报道，VZV是大多数异基因HCT后晚期(>1年)感染的原因，8年累积发病率为27%[[123](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/123)]。感染通常发生在HCT后6-9个月(第一年发生率为80%)，可能引起并发症，包括：

●皮肤播散–25%

●带状疱疹后神经痛–25%

●疤痕–20%

●细菌二重感染–15%

●死亡–5%

●中枢神经系统表现–<2%

与自体HCT相比，异基因HCT后播散更常见(45% vs 25%)[[150](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/150)]。除皮肤外，还可播散到肺部、肝脏和中枢神经系统(表现为脑膜脑炎)[[151,152](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/151,152)]。与健康成人相比，HCT受者的VZV皮损持续时间更长(10-14日)、愈合更缓慢(3-4周)[[153](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/153)]。

免疫功能不全患者不常出现水痘样皮损，无原发性皮区皮疹，这种综合征即非典型泛发性带状疱疹[[153](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/153)]。HCT后，极少有患者出现无皮疹表现的VZV感染[[154,155](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/154,155)]。血小板减少和弥漫性血管内凝血也有报道。此类感染后似乎可出现持久免疫力，因为会再次感染的患者不足5%[[153](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/153)]。

VZV再激活的危险因素包括：VZV血清学阳性、HCT前存在VZV感染、HCT前对基础肿瘤进行了广泛治疗、慢性髓系白血病以外的血液系统恶性肿瘤、强化免疫抑制(移植前放疗、移植后使用ATG)，以及需要强化免疫抑制治疗的严重广泛型慢性GVHD[[151,152,156](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/151,152,156)]。VZV也可发生于无GVHD的患者(通常在停用[阿昔洛韦](https://www.uptodate.cn/contents/zh-Hans/94044?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)后)。VZV特异性细胞免疫应答(通常在HCT后受到抑制)与VZV感染的风险呈负相关。而移植前VZV IgG抗体水平与移植后VZV再激活无相关性[[157](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/157)]。

脑炎和脑膜炎 — 植活后晚期出现脑炎和脑膜炎的原因可能与植活后早期时一样。(参见上文[‘脑炎’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H12425448))

此外，李斯特菌病虽然在HCT后不常见，植活后晚期通常也可发生[[158](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/158)]。单核细胞增多性李斯特菌(_Listeria monocytogenes_)感染基本都会累及血流，脑膜炎(2/3患者)和其他脑实质感染的发生率高，后者包括：脑炎、大脑炎、脑脓肿，极少数情况下的脑干感染(李斯特菌菱脑炎)[[159](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/159)]。使用TMP-SMX预防肺孢子菌感染并遵守食品安全指南通常可以预防李斯特菌病。(参见 [“单核细胞增多性李斯特菌感染的临床表现与诊断”，关于‘CNS感染’一节](https://www.uptodate.cn/contents/zh-Hans/clinical-manifestations-and-diagnosis-of-listeria-monocytogenes-infection?sectionName=CNS%E6%84%9F%E6%9F%93&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H6&source=see_link#H6))

隐球菌(_Cryptococcus_)是植活后晚期柔脑膜炎的少见病因。(参见 [“非HIV感染者新型隐球菌脑膜脑炎的临床表现和诊断”，关于‘临床表现’一节](https://www.uptodate.cn/contents/zh-Hans/clinical-manifestations-and-diagnosis-of-cryptococcus-neoformans-meningoencephalitis-in-patients-without-hiv?sectionName=%E4%B8%B4%E5%BA%8A%E8%A1%A8%E7%8E%B0&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H4&source=see_link#H4))

在慢性GVHD患者中，VZV是植活后晚期发生脑膜脑炎的罕见原因[[102,160,161](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/102,160,161)]。(参见 [“带状疱疹的流行病学、临床表现和诊断”，关于‘脑炎’一节](https://www.uptodate.cn/contents/zh-Hans/epidemiology-clinical-manifestations-and-diagnosis-of-herpes-zoster?sectionName=%E8%84%91%E7%82%8E&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&anchor=H2616240095&source=see_link#H2616240095))

腹泻 — 腹泻原因与植活后早期时相似。值得注意的是，与急性GVHD相比，慢性GVHD时腹泻要少见得多；因此应积极查找感染性病因，感染性病原体谱与较早期时相似。此外，EB病毒感染晚期表现可能包括胃肠道受累，伴有出血和穿孔的风险。(参见上文[‘腹泻’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H12425073))

发热 — 在植活后晚期，发热的原因可能有多种，包括GVHD、窦肺感染、中心静脉导管相关性感染、真菌感染和分枝杆菌感染。1/3的NTM病患者存在中心静脉导管相关性感染(菌血症、出口处或隧道感染)，其中大部分感染由快速生长的NTM(如，偶然分枝杆菌、脓肿分枝杆菌、龟分枝杆菌)导致[[146](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/146)]。

多种病毒可引起发热，包括CMV、EB病毒、HHV-6、腺病毒、西尼罗河病毒等。

EB病毒再激活可能涉及到附加子和/或细胞裂解模式的基因组复制模式[[162](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/162)]，可能源于供者和/或受者B细胞。大部分EB病毒再激活的患者可保持无症状。HCT受者可发生3种EB病毒相关淋巴组织增生性疾病[[105](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/105)]：

●传染性单核细胞增多症型急性疾病，可在诱导治疗后2-8周出现，特征为多克隆性B细胞增殖，无恶性转化表现

●一种类似的临床疾病，但伴有早期恶性转化特点，如细胞遗传学异常和免疫球蛋白基因重排

●PTLD–一种更严重的疾病，临床表现为发热、淋巴结肿大和/或多种器官结外淋巴瘤性增殖(肝、消化道、肺、中枢神经系统和骨髓)，其特征为单克隆B细胞增殖伴恶性细胞遗传学异常以及免疫球蛋白基因重排

不同类型HCT的PTLD发生率差异很大。T细胞重度减少的患者发生PTLD的风险最高，如T细胞去除后、使用抗T细胞抗体、脐血移植以及HLA不相合移植[[17,163-165](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/17,163-165)]。供/受者EB病毒血清学不匹配、既往EB病毒再激活和脾脏切除是PTLD的其他危险因素，危险因素数量越多，PTLD风险越高[[105,166](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/105,166)]。

PTLD急缓不一，从惰性到爆发性不等。累及范围不一，从局部结节病灶到广泛播散性疾病不等[[105,167](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/105,167)]。PTLD详见其他专题。(参见 [“移植后淋巴增殖性疾病的流行病学、临床表现和诊断”](https://www.uptodate.cn/contents/zh-Hans/epidemiology-clinical-manifestations-and-diagnosis-of-post-transplant-lymphoproliferative-disorders?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“移植后淋巴增殖性疾病的治疗和预防”](https://www.uptodate.cn/contents/zh-Hans/treatment-and-prevention-of-post-transplant-lymphoproliferative-disorders?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

患者教育UpToDate提供两种类型的患者教育资料：“基础篇”和“高级篇”。基础篇通俗易懂，相当于5-6年级阅读水平(美国)，可以解答关于某种疾病患者可能想了解的4-5个关键问题；基础篇更适合想了解疾病概况且喜欢阅读简短易读资料的患者。高级篇篇幅较长，内容更深入详尽；相当于10-12年级阅读水平(美国)，适合想深入了解并且能接受一些医学术语的患者。

以下是与此专题相关的患者教育资料。我们建议您以打印或电子邮件的方式给予患者。(您也可以通过检索“患者教育”和关键词找到更多相关专题内容。)

●基础篇(参见 [“患者教育：癌症治疗患者的中性粒细胞减少和发热(基础篇)”](https://www.uptodate.cn/contents/zh-Hans/neutropenia-and-fever-in-people-being-treated-for-cancer-the-basics?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

总结

●造血干细胞移植(HCT)后的大部分并发症都可能存在多种感染性和非感染性原因([表 3](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=ID%2F50318&topicKey=ID%2F1403&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&rank=1%7E150&source=see_link))。(参见上文[‘引言’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H3926169))

●感染性病原体和感染性综合征因HCT后的时期而异；异基因HCT后([图 2](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=ID%2F52716&topicKey=ID%2F1403&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&rank=1%7E150&source=see_link))的感染风险比自体HCT([图 3](https://www.uptodate.cn/contents/zh-Hans/image?imageKey=ID%2F64491&topicKey=ID%2F1403&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&rank=1%7E150&source=see_link))高。(参见上文[‘感染时间轴’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H503783707))

●HCT前的感染评估和HCT受者的感染预防详见其他专题。(参见 [“造血干细胞移植前的感染评估”](https://www.uptodate.cn/contents/zh-Hans/evaluation-for-infection-before-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“造血干细胞移植受者感染的预防”](https://www.uptodate.cn/contents/zh-Hans/prevention-of-infections-in-hematopoietic-cell-transplant-recipients?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“血液系统恶性肿瘤成人患者中侵袭性真菌感染的预防”](https://www.uptodate.cn/contents/zh-Hans/prophylaxis-of-invasive-fungal-infections-in-adults-with-hematologic-malignancies?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“造血干细胞移植受者的病毒感染预防”](https://www.uptodate.cn/contents/zh-Hans/prevention-of-viral-infections-in-hematopoietic-cell-transplant-recipients?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“造血干细胞移植候选者和移植受者的免疫接种”](https://www.uptodate.cn/contents/zh-Hans/immunizations-in-hematopoietic-cell-transplant-candidates-and-recipients?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

植活前

●在植活前，中性粒细胞减少性发热常见，其原因、评估和处理策略与高风险非HCT患者一样。(参见上文[‘中性粒细胞减少性发热’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H12424739)和 [“中性粒细胞减少性发热综合征的概述”](https://www.uptodate.cn/contents/zh-Hans/overview-of-neutropenic-fever-syndromes?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“成人癌症患者中性粒细胞减少性发热的诊断方法”](https://www.uptodate.cn/contents/zh-Hans/diagnostic-approach-to-the-adult-cancer-patient-with-neutropenic-fever?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“血液系统恶性肿瘤成人患者及造血干细胞移植受者(高危患者)的中性粒细胞减少性发热综合征的治疗”](https://www.uptodate.cn/contents/zh-Hans/treatment-of-neutropenic-fever-syndromes-in-adults-with-hematologic-malignancies-and-hematopoietic-cell-transplant-recipients-high-risk-patients?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

●腹泻常由艰难梭菌或中性粒细胞减少性小肠结肠炎(盲肠炎)引起，但也可能是由于非感染性因素，如预处理引起的黏膜损伤，或药物反应。(参见上文[‘腹泻’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H12424899)和 [“成人艰难梭菌感染的流行病学、微生物学和病理生理学”](https://www.uptodate.cn/contents/zh-Hans/clostridioides-difficile-infection-in-adults-epidemiology-microbiology-and-pathophysiology?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“成人艰难梭菌感染的临床表现和诊断”](https://www.uptodate.cn/contents/zh-Hans/clostridioides-difficile-infection-in-adults-clinical-manifestations-and-diagnosis?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link)和 [“中性粒细胞减少性小肠结肠炎(盲肠炎)”](https://www.uptodate.cn/contents/zh-Hans/neutropenic-enterocolitis-typhlitis?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&topicRef=1403&source=see_link))

●在植活前，弥漫性肺浸润的病因主要为非感染性因素，如预处理方案引起的肺水肿或肺损伤，但偶见呼吸道病毒感染。结节性肺炎大多由感染引起，G+或G-菌最常见，但偶由曲霉菌引起。(参见上文[‘肺炎’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H12424964))

植活后早期

●在植活后早期，弥漫性肺炎可分为非感染性(预处理方案毒性)和感染性[巨细胞病毒(CMV)、呼吸道病毒、肺孢子菌肺炎(PCP)]，各占一半。结节性肺炎大多由感染引起，细菌(G+和G-)和曲霉菌(或其他霉菌，但相对少见)各占一半。(参见上文[‘肺炎’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H12425011))

●腹泻原因可能是药物反应、移植物抗宿主病(GVHD)、艰难梭菌或CMV。(参见上文[‘腹泻’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H12425073))

●肝细胞损伤原因可能是药物毒性、GVHD或既往肝炎患者发生肝炎病毒再激活。(参见上文[‘肝炎’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H12425087))

●脑炎原因可能是药物毒性或者一些病毒，包括人疱疹病毒6型(HHV-6)、CMV、水痘-带状疱疹病毒(VZV)、单纯疱疹病毒(HSV)、JC多瘤病毒(JCPyV)、西尼罗河病毒或EB病毒。(参见上文[‘脑炎’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H12425448))

●出血性膀胱炎最常见原因是BK多瘤病毒(BKPyV)，而腺病毒则是较少见的病因，更少见的原因包括：其他感染(CMV、JCPyV)、血液系统病因(出血性疾病、血小板减少症，可能还有GVHD)和预处理损伤。(参见上文[‘出血性膀胱炎’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H12425433))

植活后晚期

●在植活后晚期，尤其是伴慢性GVHD的患者，窦肺感染常由荚膜细菌引起。(参见上文[‘植活后晚期’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H3926190))

●弥漫性肺炎可分为非感染性[隐源性机化性肺炎(COP)]和感染性(CMV、呼吸道病毒、PCP)，各占一半。结节性肺炎大多由感染引起，G+或G-菌最常见，但偶由曲霉菌、其他霉菌或诺卡菌引起。(参见上文[‘肺炎’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H1909225389))

●VZV感染常发生于HCT后晚期。(参见上文[‘皮损’](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E5%90%8E%E6%84%9F%E6%9F%93%E6%A6%82%E8%BF%B0&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H12425590))

致谢UpToDate公司的编辑人员感谢Dr. Elias Anaissie和Dr. Kieren A Marr对本专题早期版本做出的贡献。

使用UpToDate临床顾问须遵循[使用条款](https://www.uptodate.cn/legal/china/license).

参考文献

1.  [Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect Dis Clin North Am 2010; 24:257.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/1)
2.  [Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009; 49:1211.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/2)
3.  [Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998; 129:559.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/3)
4.  [Mullighan CG, Heatley SL, Danner S, et al. Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation. Blood 2008; 112:2120.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/4)
5.  [Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008; 359:1766.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/5)
6.  [Cunha C, Aversa F, Lacerda JF, et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med 2014; 370:421.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/6)
7.  [Cunha C, Di Ianni M, Bozza S, et al. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood 2010; 116:5394.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/7)
8.  [Chai LY, de Boer MG, van der Velden WJ, et al. The Y238X stop codon polymorphism in the human β-glucan receptor dectin-1 and susceptibility to invasive aspergillosis. J Infect Dis 2011; 203:736.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/8)
9.  [Camargo JF, Husain S. Immune correlates of protection in human invasive aspergillosis. Clin Infect Dis 2014; 59:569.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/9)
10.  [Zaia JA, Sun JY, Gallez-Hawkins GM, et al. The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15:315.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/10)
11.  [Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/11)
12.  [Paesmans M, Klastersky J, Maertens J, et al. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter? Support Care Cancer 2011; 19:1001.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/12)
13.  [Uys A, Rapoport BL, Anderson R. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 2004; 12:555.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/13)
14.  [Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 2006; 24:4129.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/14)
15.  [Nichols WG, Corey L, Gooley T, et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185:273.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/15)
16.  [Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007; 110:4606.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/16)
17.  [Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/17)
18.  [Small TN, Papadopoulos EB, Boulad F, et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999; 93:467.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/18)
19.  [Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/19)
20.  [Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328:1323.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/20)
21.  [Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/21)
22.  [Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/22)
23.  [Wingard JR. Infections in allogeneic bone marrow transplant recipients. Semin Oncol 1993; 20:80.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/23)
24.  [Prentice HG, Hann IM. Antiviral therapy in the immunocompromised patient. Br Med Bull 1985; 41:367.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/24)
25.  [Chakrabarti S, Lees A, Jones SG, Milligan DW. Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality. Bone Marrow Transplant 2000; 26:871.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/25)
26.  [Arango JI, Restrepo A, Schneider DL, et al. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant 2006; 37:517.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/26)
27.  [Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2012; 54:1053.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/27)
28.  [Dubberke ER, Reske KA, Olsen MA, et al. Epidemiology and outcomes of Clostridium difficile infection in allogeneic hematopoietic cell and lung transplant recipients. Transpl Infect Dis 2018; 20:e12855.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/28)
29.  [Wingard JR, Hiemenz JW, Jantz MA. How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation. Blood 2012; 120:1791.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/29)
30.  [Zaia J, Baden L, Boeckh MJ, et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009; 44:471.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/30)
31.  [Bedi A, Miller CB, Hanson JL, et al. Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol 1995; 13:1103.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/31)
32.  [Almyroudis NG, Fuller A, Jakubowski A, et al. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis 2005; 7:11.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/32)
33.  [Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48:265.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/33)
34.  [Jantunen E, Ruutu P, Piilonen A, et al. Treatment and outcome of invasive Aspergillus infections in allogeneic BMT recipients. Bone Marrow Transplant 2000; 26:759.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/34)
35.  [Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45:1161.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/35)
36.  [Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/36)
37.  [Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102:827.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/37)
38.  [Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/38)
39.  [Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992; 14 Suppl 1:S43.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/39)
40.  [De Castro N, Neuville S, Sarfati C, et al. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant 2005; 36:879.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/40)
41.  [Roblot F, Imbert S, Godet C, et al. Risk factors analysis for Pneumocystis jiroveci pneumonia (PCP) in patients with haematological malignancies and pneumonia. Scand J Infect Dis 2004; 36:848.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/41)
42.  [Souza JP, Boeckh M, Gooley TA, et al. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis 1999; 29:1467.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/42)
43.  [Williams KM, Ahn KW, Chen M, et al. The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. Bone Marrow Transplant 2016; 51:573.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/43)
44.  [Sangiolo D, Storer B, Nash R, et al. Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. Biol Blood Marrow Transplant 2005; 11:521.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/44)
45.  [Vasconcelles MJ, Bernardo MV, King C, et al. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant 2000; 6:35.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/45)
46.  [Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004; 39:1300.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/46)
47.  [Parody R, Rabella N, Martino R, et al. Upper and lower respiratory tract infections by human enterovirus and rhinovirus in adult patients with hematological malignancies. Am J Hematol 2007; 82:807.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/47)
48.  [Nichols WG, Corey L, Gooley T, et al. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001; 98:573.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/48)
49.  [Ison MG, Hayden FG, Kaiser L, et al. Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Clin Infect Dis 2003; 36:1139.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/49)
50.  [Gluckman E, Traineau R, Devergie A, et al. Prevention and treatment of CMV infection after allogeneic bone marrow transplant. Ann Hematol 1992; 64 Suppl:A158.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/50)
51.  [Wingard JR, Chen DY, Burns WH, et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood 1988; 71:1432.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/51)
52.  [Ljungman P, Biron P, Bosi A, et al. Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients. Infectious Disease Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994; 13:209.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/52)
53.  [Boeckh M, Gooley TA, Reusser P, et al. Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. J Infect Dis 1995; 172:939.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/53)
54.  [Orlent H, Crawley C, Cwynarski K, et al. Strongyloidiasis pre and post autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 32:115.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/54)
55.  [Qazilbash MH, Ueno NT, Hosing C, et al. Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 38:393.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/55)
56.  [Schmidt M, Sonneville R, Schnell D, et al. Clinical features and outcomes in patients with disseminated toxoplasmosis admitted to intensive care: a multicenter study. Clin Infect Dis 2013; 57:1535.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/56)
57.  [Busemann C, Ribback S, Zimmermann K, et al. Toxoplasmosis after allogeneic stem cell transplantation--a single centre experience. Ann Hematol 2012; 91:1081.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/57)
58.  [Nomura K, Fujimoto Y, Yamashita M, et al. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand J Gastroenterol 2009; 44:74.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/58)
59.  [Chopra T, Chandrasekar P, Salimnia H, et al. Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant 2011; 25:E82.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/59)
60.  [Trifilio S, Helenowski I, Giel M, et al. Questioning the role of a neutropenic diet following hematopoetic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18:1385.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/60)
61.  [Lindemans CA, Leen AM, Boelens JJ. How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood 2010; 116:5476.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/61)
62.  [Bertheau P, Parquet N, Ferchal F, et al. Fulminant adenovirus hepatitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 17:295.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/62)
63.  [Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002; 100:1619.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/63)
64.  [La Rosa AM, Champlin RE, Mirza N, et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 2001; 32:871.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/64)
65.  [Robin M, Marque-Juillet S, Scieux C, et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. Haematologica 2007; 92:1254.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/65)
66.  [Lee YJ, Chung D, Xiao K, et al. Adenovirus viremia and disease: comparison of T cell-depleted and conventional hematopoietic stem cell transplantation recipients from a single institution. Biol Blood Marrow Transplant 2013; 19:387.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/66)
67.  [Myers GD, Krance RA, Weiss H, et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant 2005; 36:1001.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/67)
68.  [Matthes-Martin S, Feuchtinger T, Shaw PJ, et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis 2012; 14:555.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/68)
69.  [Yolken RH, Bishop CA, Townsend TR, et al. Infectious gastroenteritis in bone-marrow-transplant recipients. N Engl J Med 1982; 306:1010.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/69)
70.  [Roddie C, Paul JP, Benjamin R, et al. Allogeneic hematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognized cause of morbidity. Clin Infect Dis 2009; 49:1061.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/70)
71.  [Schwartz S, Vergoulidou M, Schreier E, et al. Norovirus gastroenteritis causes severe and lethal complications after chemotherapy and hematopoietic stem cell transplantation. Blood 2011; 117:5850.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/71)
72.  [Liakopoulou E, Mutton K, Carrington D, et al. Rotavirus as a significant cause of prolonged diarrhoeal illness and morbidity following allogeneic bone marrow transplantation. Bone Marrow Transplant 2005; 36:691.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/72)
73.  [Nachbaur D, Kropshofer G, Feichtinger H, et al. Cryptosporidiosis after CD34-selected autologous peripheral blood stem cell transplantation (PBSCT). Treatment with paromomycin, azithromycin and recombinant human interleukin-2. Bone Marrow Transplant 1997; 19:1261.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/73)
74.  [Müller CI, Zeiser R, Grüllich C, et al. Intestinal cryptosporidiosis mimicking acute graft-versus-host disease following matched unrelated hematopoietic stem cell transplantation. Transplantation 2004; 77:1478.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/74)
75.  [Park SC, Jeong SH, Kim J, et al. High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin's lymphoma in Korea. J Med Virol 2008; 80:960.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/75)
76.  [Uhm JE, Kim K, Lim TK, et al. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13:463.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/76)
77.  [Ceneli O, Ozkurt ZN, Acar K, et al. Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients. World J Gastroenterol 2010; 16:1765.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/77)
78.  [Mya DH, Han ST, Linn YC, et al. Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. Ann Oncol 2012; 23:421.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/78)
79.  [Locasciulli A, Bruno B, Alessandrino EP, et al. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant 2003; 31:295.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/79)
80.  [Ramos CA, Saliba RM, de Pádua L, et al. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 2009; 94:249.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/80)
81.  [Peffault de Latour R, Ribaud P, Robin M, et al. Allogeneic hematopoietic cell transplant in HCV-infected patients. J Hepatol 2008; 48:1008.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/81)
82.  [McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology 2010; 51:1450.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/82)
83.  [Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999; 29:1893.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/83)
84.  [Erard V, Storer B, Corey L, et al. BK virus infection in hematopoietic stem cell transplant recipients: frequency, risk factors, and association with postengraftment hemorrhagic cystitis. Clin Infect Dis 2004; 39:1861.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/84)
85.  Hirsch HH, Pergam SA. Human Adenovirus, Polyomavirus, and Parvovirus Infections in Patients Undergoing Hematopoietic Stem Cell Transplantation. In: Thomas' Hematopoietic Cell Transplantation, 5th ed, Forman SJ, Negrin RS, Antin JH, et al (Eds), Wiley-Blackwell, Chichester, West Sussex 2016.
86.  [Giraud G, Priftakis P, Bogdanovic G, et al. BK-viruria and haemorrhagic cystitis are more frequent in allogeneic haematopoietic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts. Bone Marrow Transplant 2008; 41:737.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/86)
87.  [Dalianis T, Ljungman P. Full myeloablative conditioning and an unrelated HLA mismatched donor increase the risk for BK virus-positive hemorrhagic cystitis in allogeneic hematopoetic stem cell transplanted patients. Anticancer Res 2011; 31:939.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/87)
88.  [Silva Lde P, Patah PA, Saliba RM, et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica 2010; 95:1183.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/88)
89.  [Park SH, Choi SM, Lee DG, et al. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin. Transpl Infect Dis 2009; 11:413.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/89)
90.  [Fioriti D, Degener AM, Mischitelli M, et al. BKV infection and hemorrhagic cystitis after allogeneic bone marrow transplant. Int J Immunopathol Pharmacol 2005; 18:309.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/90)
91.  [Cesaro S, Facchin C, Tridello G, et al. A prospective study of BK-virus-associated haemorrhagic cystitis in paediatric patients undergoing allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41:363.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/91)
92.  [Erard V, Kim HW, Corey L, et al. BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. Blood 2005; 106:1130.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/92)
93.  [Haines HL, Laskin BL, Goebel J, et al. Blood, and not urine, BK viral load predicts renal outcome in children with hemorrhagic cystitis following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17:1512.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/93)
94.  [Hwang YY, Sim J, Leung AY, et al. BK virus-associated bilateral ureteric stenosis after haematopoietic SCT: viral kinetics and successful treatment. Bone Marrow Transplant 2013; 48:745.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/94)
95.  [Khan H, Oberoi S, Mahvash A, et al. Reversible ureteral obstruction due to polyomavirus infection after percutaneous nephrostomy catheter placement. Biol Blood Marrow Transplant 2011; 17:1551.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/95)
96.  [O'Donnell PH, Swanson K, Josephson MA, et al. BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. Biol Blood Marrow Transplant 2009; 15:1038.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/96)
97.  [Ljungman P, Wang FZ, Clark DA, et al. High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. Br J Haematol 2000; 111:774.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/97)
98.  [Yoshikawa T, Asano Y, Ihira M, et al. Human herpesvirus 6 viremia in bone marrow transplant recipients: clinical features and risk factors. J Infect Dis 2002; 185:847.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/98)
99.  [Zerr DM, Corey L, Kim HW, et al. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis 2005; 40:932.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/99)
100.  [Hentrich M, Oruzio D, Jäger G, et al. Impact of human herpesvirus-6 after haematopoietic stem cell transplantation. Br J Haematol 2005; 128:66.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/100)
101.  [Wu M, Huang F, Jiang X, et al. Herpesvirus-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation. PLoS One 2013; 8:e77805.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/101)
102.  [Schmidt-Hieber M, Schwender J, Heinz WJ, et al. Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents. Haematologica 2011; 96:142.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/102)
103.  [Reddy SM, Winston DJ, Territo MC, Schiller GJ. CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency. Bone Marrow Transplant 2010; 45:979.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/103)
104.  [Hubacek P, Keslova P, Formankova R, et al. Cytomegalovirus encephalitis/retinitis in allogeneic haematopoietic stem cell transplant recipient treated successfully with combination of cidofovir and foscarnet. Pediatr Transplant 2009; 13:919.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/104)
105.  [Reddy N, Rezvani K, Barrett AJ, Savani BN. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant 2011; 17:591.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/105)
106.  [Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int 2005; 17:658.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/106)
107.  [Wang Y, Kirby JE, Qian Q. Effective use of JC virus PCR for diagnosis of progressive multifocal leukoencephalopathy. J Med Microbiol 2009; 58:253.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/107)
108.  [Mateen FJ, Muralidharan R, Carone M, et al. Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol 2011; 70:305.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/108)
109.  [Lejniece S, Murovska M, Chapenko S, et al. Progressive multifocal leukoencephalopathy following fludarabine treatment in a chronic lymphocytic leukemia patient. Exp Oncol 2011; 33:239.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/109)
110.  [D'Souza A, Wilson J, Mukherjee S, Jaiyesimi I. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature. Clin Lymphoma Myeloma Leuk 2010; 10:E1.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/110)
111.  [Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol 2010; 47:187.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/111)
112.  [Yokoyama H, Watanabe T, Maruyama D, et al. Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature. Int J Hematol 2008; 88:443.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/112)
113.  [Reddy P, Davenport R, Ratanatharathorn V, et al. West Nile virus encephalitis causing fatal CNS toxicity after hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 33:109.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/113)
114.  [Brenner W, Storch G, Buller R, et al. West Nile Virus encephalopathy in an allogeneic stem cell transplant recipient: use of quantitative PCR for diagnosis and assessment of viral clearance. Bone Marrow Transplant 2005; 36:369.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/114)
115.  [Goebel WS, Conway JH, Faught P, et al. Disseminated toxoplasmosis resulting in graft failure in a cord blood stem cell transplant recipient. Pediatr Blood Cancer 2007; 48:222.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/115)
116.  [Duband S, Cornillon J, Tavernier E, et al. Toxoplasmosis with hemophagocytic syndrome after bone marrow transplantation: diagnosis at autopsy. Transpl Infect Dis 2008; 10:372.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/116)
117.  [Power M, Vandenberghe E, Conneally E, et al. Retinal and cerebral toxoplasmosis following nonmyeloablative stem cell transplant for chronic lymphocytic leukaemia. Bone Marrow Transplant 2005; 36:1019.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/117)
118.  [Meers S, Lagrou K, Theunissen K, et al. Myeloablative conditioning predisposes patients for Toxoplasma gondii reactivation after allogeneic stem cell transplantation. Clin Infect Dis 2010; 50:1127.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/118)
119.  [Derouin F, Pelloux H, ESCMID Study Group on Clinical Parasitology. Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect 2008; 14:1089.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/119)
120.  [Edvinsson B, Lundquist J, Ljungman P, et al. A prospective study of diagnosis of Toxoplasma gondii infection after bone marrow transplantation. APMIS 2008; 116:345.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/120)
121.  [Lim Z, Baker B, Zuckerman M, et al. Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation. J Infect 2007; 54:e83.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/121)
122.  [Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol 1999; 246:339.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/122)
123.  [Robin M, Porcher R, De Castro Araujo R, et al. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Biol Blood Marrow Transplant 2007; 13:1304.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/123)
124.  [Ochs L, Shu XO, Miller J, et al. Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood 1995; 86:3979.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/124)
125.  [Hoyle C, Goldman JM. Life-threatening infections occurring more than 3 months after BMT. 18 UK Bone Marrow Transplant Teams. Bone Marrow Transplant 1994; 14:247.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/125)
126.  [Youssef S, Rodriguez G, Rolston KV, et al. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989-2005. Medicine (Baltimore) 2007; 86:69.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/126)
127.  [Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28:250.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/127)
128.  [Ljungman P, Engelhard D, de la Cámara R, et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 2005; 35:737.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/128)
129.  [Kulkarni S, Powles R, Treleaven J, et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 2000; 95:3683.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/129)
130.  [Sheridan JF, Tutschka PJ, Sedmak DD, Copelan EA. Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. Blood 1990; 75:1583.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/130)
131.  [Cuthbert RJ, Iqbal A, Gates A, et al. Functional hyposplenism following allogeneic bone marrow transplantation. J Clin Pathol 1995; 48:257.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/131)
132.  [Elias M, Bisharat N, Goldstein LH, et al. Pneumococcal sepsis due to functional hyposplenism in a bone marrow transplant patient. Eur J Clin Microbiol Infect Dis 2004; 23:212.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/132)
133.  [Ozdemir E, Saliba RM, Champlin RE, et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 2007; 40:125.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/133)
134.  [Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006; 91:78.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/134)
135.  [Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am 2011; 25:151.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/135)
136.  [Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101:407.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/136)
137.  [Krause H, Hebart H, Jahn G, et al. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 1997; 19:1111.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/137)
138.  [Li CR, Greenberg PD, Gilbert MJ, et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83:1971.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/138)
139.  [Peleg AY, Husain S, Qureshi ZA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007; 44:1307.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/139)
140.  [Roy V, Weisdorf D. Mycobacterial infections following bone marrow transplantation: a 20 year retrospective review. Bone Marrow Transplant 1997; 19:467.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/140)
141.  [Navari RM, Sullivan KM, Springmeyer SC, et al. Mycobacterial infections in marrow transplant patients. Transplantation 1983; 36:509.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/141)
142.  [Kurzrock R, Zander A, Vellekoop L, et al. Mycobacterial pulmonary infections after allogeneic bone marrow transplantation. Am J Med 1984; 77:35.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/142)
143.  [Hughes WT. Mycobacterial infections in bone marrow transplant recipients. Biol Blood Marrow Transplant 2000; 6:359.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/143)
144.  [Gaviria JM, Garcia PJ, Garrido SM, et al. Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: characteristics of respiratory and catheter-related infections. Biol Blood Marrow Transplant 2000; 6:361.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/144)
145.  [Akan H, Arslan O, Akan OA. Tuberculosis in stem cell transplant patients. J Hosp Infect 2006; 62:421.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/145)
146.  [Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004; 38:1428.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/146)
147.  [van der Eijk AA, Pas SD, Cornelissen JJ, de Man RA. Hepatitis E virus infection in hematopoietic stem cell transplant recipients. Curr Opin Infect Dis 2014; 27:309.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/147)
148.  [Peritz DC, Duncan C, Kurek K, et al. Visceral varicella zoster virus (VZV) after allogeneic hematopoietic stem cell transplant (HSCT) in pediatric patients with chronic graft-versus-host disease (cGVHD). J Pediatr Hematol Oncol 2008; 30:931.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/148)
149.  [Kawasaki H, Takayama J, Ohira M. Herpes zoster infection after bone marrow transplantation in children. J Pediatr 1996; 128:353.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/149)
150.  [Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985; 152:1172.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/150)
151.  Fetscher S, Technau K, Lange W. Herpes zoster after high dose chemotherapy and autologous stem cell transplantation. In: 25th annual meeting European group for blood and marrow transplanation and 15th meeting of the nurses group; 1999 March 21-25; Hamburg, Germany.
152.  Wessels M, Nevill T, Le A, et al. Incidence and factors predictive of varicella-zoster virus infection following stem cell transplantation. In: 25th annual meeting European Group for blood and marrow transplantation and 15th meeting of the nurses group; 1999 March 21-25; Hamburg, Germany.
153.  [Atkinson K, Meyers JD, Storb R, et al. Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia. Transplantation 1980; 29:47.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/153)
154.  [Hon C, Au WY, Cheng VC. Ophthalmic zoster sine herpete presenting as oculomotor palsy after marrow transplantation for acute myeloid leukemia. Haematologica 2005; 90:EIM04.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/154)
155.  [Patel SR, Ortín M. Varicella-zoster reactivation in a patient receiving routine revaccinations after an allogeneic hemopoietic progenitors transplant. J Pediatr Hematol Oncol 2005; 27:106.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/155)
156.  [Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 1994; 13:277.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/156)
157.  [Webster A, Grint P, Brenner MK, et al. Titration of IgG antibodies against varicella zoster virus before bone marrow transplantation is not predictive of future zoster. J Med Virol 1989; 27:117.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/157)
158.  [Safdar A, Papadopoulous EB, Armstrong D. Listeriosis in recipients of allogeneic blood and marrow transplantation: thirteen year review of disease characteristics, treatment outcomes and a new association with human cytomegalovirus infection. Bone Marrow Transplant 2002; 29:913.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/158)
159.  [Clauss HE, Lorber B. Central nervous system infection with Listeria monocytogenes. Curr Infect Dis Rep 2008; 10:300.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/159)
160.  [Suzuki J, Ashizawa M, Okuda S, et al. Varicella zoster virus meningoencephalitis after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2012; 14:E7.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/160)
161.  [Fukuno K, Tomonari A, Takahashi S, et al. Varicella-zoster virus encephalitis in a patient undergoing unrelated cord blood transplantation for myelodysplastic syndrome-overt leukemia. Int J Hematol 2006; 84:79.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/161)
162.  [Funk GA, Gosert R, Hirsch HH. Viral dynamics in transplant patients: implications for disease. Lancet Infect Dis 2007; 7:460.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/162)
163.  [Juvonen E, Aalto SM, Tarkkanen J, et al. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant 2003; 32:97.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/163)
164.  [Bokhari S, Das-Gupta E, Russell N, Byrne J. Post-transplant lymphoproliferative disease following reduced intensity conditioning transplants incorporating alemtuzumab. Bone Marrow Transplant 2008; 42:281.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/164)
165.  [Snyder MJ, Stenzel TT, Buckley PJ, et al. Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. Am J Surg Pathol 2004; 28:794.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/165)
166.  [Islam MS, Anoop P, Gordon-Smith EC, et al. Epstein-Barr virus infections after allogeneic stem cell transplantation: a comparison between non-malignant and malignant hematological disorders. Hematology 2010; 15:344.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/166)
167.  [Cohen JI, Jaffe ES, Dale JK, et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood 2011; 117:5835.](https://www.uptodate.cn/contents/zh-Hans/overview-of-infections-following-hematopoietic-cell-transplantation/abstract/167)

专题 1403 版本 25.0.zh-Hans.1.0